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SUMMARY 
I performed my doctorate research activity studying three important human pathogens that 
are A-B toxins: Diphtheria Toxin (DT), Tetanus Neurotoxin (TeNT) and Botulinum neurotoxins 
(BoNTs), the etiologic agents of diphtheria, tetanus and botulism respectively. In terms of 
structural organization these toxins consist of three domains, which are termed L chain (the 
N-terminal catalytic domain), HN (the transmembrane domain), and HC (the C-terminal 
binding domain). These domains are closely related to the common four step mechanism of 
action: membrane binding mediated by HC, endocytosis, membrane translocation mediated 
by HN and L-chain mediated substrate modification.  
I studied the conformational change of diphtheria toxin at acidic pH. DT includes a T domain 
which is known to mediate the pH-dependent membrane translocation, by forming a 
channel through which the catalytic domain crosses the endocytic vesicle membrane. To date 
no structural data are available about the pore/channel formed by the T domain, nor is 
known if it is monomeric or oligomeric. I have performed biochemical and structural studies 
to characterize the T domain of DT. The T domain is also considered a prospective anti-cancer 
agent for the targeted delivery of cytotoxic therapy to cancer cells. I obtained the crystal 
structure of DT in the presence of lipid bicelles (which simulate the endocytic vesicle 
membrane) and grown at pH 5.5, pH that mimics the acidic environment where translocation 
takes place. The reported structure throws lights on the initial event of this process, the 
destabilization of the three α-helices present at the bottom of the toxin (Leka et al., 2014). 
I then worked on a project which aimed to unravel the three dimensional structure of 
tetanus neurotoxin by crystallization studies. Because TeNT is considered “uncrystallizable” I 
focused on the use of antibody fragments (Fabs) as crystallization chaperons to aid the 
structural determination. Native gel analysis and size exclusion chromatography showed the 
formation of a stable complex in vitro between TeNT and the relative Fabs. Several 
crystallization experiments were carried out by high throughput crystallization screens.  
Further, I performed functional analysis on the trafficking of botulinum neurotoxin at the 
neuromuscular junction (NMJ). I expressed the binding domains of different BoNT serotypes, 
which are both necessary and sufficient for binding to the neuronal surface and 
internalization. The two step purifications, chromatography and gel filtration, were sufficient 
to yield purifications of each binding domain to >90% purity. Using cerebellum granular 
neurons (CGNs), I tested their functionality and specificity. I performed also in vivo assays in 
order to analyze their distribution along the NMJ. The data from fluorescence analysis show 
high specificity of these binding domains at the NMJ, and a different staining between 
different BoNT serotypes, reflecting their different time of intoxication, and perhaps a 
different pathway of vesicular trafficking.                                 
 
 
 
 
 
RIASSUNTO 
Ho effettuato la mia attività di ricerca studiando tre importanti patogeni umani, che sono 
tossine di tipo A-B: la tossina difterica (DT), la neurotossina tetanica (TeNT) e le neurotossine 
botuliniche (BoNTs), gli agenti eziologici di difterite, tetano e botulismo, rispettivamente. In 
termini di organizzazione strutturale queste tossine sono costituite da tre domini: il dominio 
catalitico (LH), il dominio di translocazione (HN) e il dominio di legame (HC). Questa 
organizzazione dei domini è strettamente correlata al loro comune meccanismo d’azione che 
comprende: il legame alla membrane cellulare mediato dal HC, la traslocazione del dominio 
catalitico nel citoplasma mediata dal canale di permeazione formato dal HN. 
Ho studiato il cambiamento conformazionale della tossina difterica a pH acido. DT include un 
dominio di translocazione (dominio T), che forma il canale attraverso il quale il dominio 
catalitico attraversa la membrana della vescicola endosomica. Fino ad oggi non ci sono dati 
strutturali che riguardano il canale formato dal dominio T, non si sa neanche se è un 
monomero o oligomero. Ho eseguito studi biochimici e strutturali per caratterizzare il 
dominio T di DT. Il dominio T è anche considerato un agente anti-cancro nelle terapie mirate 
contro le cellule tumorali. Ho ottenuto la struttura tridimensionale della tossina difterica in 
presenza di doppi strati lipidici (che simulano la membrana della vescicola endosomica) ed in 
condizioni di pH 5,5 (pH corrispondente all'ambiente acido in cui avviene la il processo di 
traslocazione). La struttura riportata getta luci sull'evento iniziale di questo processo, la 
destabilizzazione di tre alfa-eliche presenti nella parte inferiore della tossina (Leka et al., 
2014). 
Ho poi lavorato su un progetto che mirava a caratterizzare la struttura tridimensionale della 
tosssina tetanica. Poiché la cristallizzazione di questa tossina risulta d’essere molto difficile, 
mi sono concentrata sull'utilizzo di frammenti di anticorpi (Fab) come tools per aiutare la 
determinazione strutturale. Analisi da gel nativo e da cromatografia ad esclusione mostrano 
la formazione di un complesso stabile in vitro tra la tossina ed i relativi Fab. Diversi 
esperimenti di cristallizzazione sono stati eseguiti, e per il momento non abbiamo ancora 
informazioni strutturali sulla tossina. 
Inoltre, ho studiato anche la localizzazione ed il processo di internalizzazione delle tossine 
botuliniche a livello della giunzione neuromuscolare (NMJ). Ho espresso i domini di legame di 
diversi sierotipi di tossine botuliniche, domini che sono necessari e sufficienti per il legame 
alla superficie dei neuroni. I domini di legame sono stati purificati utilizzando cromatografia 
di affinità e per esclusione, ottendo alla fine una purezza > 90% . Utilizzando i neuroni 
granulari di cervelletto (CGN), ho testato la loro funzionalità e specificità. Questi domini sono 
stati iniettati in vivo al fine di analizzare la loro localizzazione a livello della giunzione 
neuromuscolare. I dati ottenuti con analisi di microscopia confocale ed a fluorescenza 
mostrano che questi domini si localizzano proprio a livello della giunzione muscolare. Nelle 
marcature si osserva anche una colorazione diversa tra i diversi sierotipi BoNT, e questo 
risultato riflette il diverso tempo di intossicazione tra i vari serotipi di tossine botuliniche, e 
forse anche una diversa localizzazione in diverse vescicole endosomiche.  
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 INTRODUCTION 
1. Bacterial protein toxins 
Toxins are virulence factors produced by pathogenic bacteria to colonise and/or to multiply 
within the animal host. Bacterial protein toxins have reached an amazing level of 
specialisation and adaptation to the targeted organism or cell type in order to achieve an 
efficient subversion of host cell function. The study of host-pathogen interactions has offered 
scientists different strategies that have resulted from the evolutionary race between 
eukaryotic cells and competing microorganisms. The result of this evolutionary pressure was 
the identification of several virulence factors/proteins that interfere with fundamental 
cellular processes (Schiavo et al., 2001; Kahn et al., 2002). The biochemical analysis of these 
molecules and the characterization of their cellular mechanism of action have yielded several 
targets for vaccine development and therapeutic intervention. 
 
1.1 A-B toxins 
A huge number of proteins produced by bacterial pathogens are highly toxic to mammalian 
cells due to their ability to attack/destroy essential cellular metabolic and/or signal 
transduction pathways. These toxic proteins mostly belong to the A-B toxin family (Barth et 
al., 2004). A-B toxins are composed by two structurally and functionally distinctive 
protomers: A and B. The protomer B is generated only after proteolysis of the precursor 
molecules. It mediates the binding to a specific receptor on the host cell membrane. The B 
protomer-receptor complex then acts as a docking platform that subsequently translocates 
the enzymatic A component into the cytosol via acidified vesicular compartments. Once 
inside the cytosol, the A protomer can inhibit normal cell function. Not only these toxins are 
important virulence factors, but also they are useful biological tools for studying several 
cellular functions and delivering heterologous proteins into endosomal, as well as cytosolic 
compartments. Usually, an A-B toxin is synthesized and secreted from the bacteria pathogen 
as an inactive form. The inactive precursor is then activated through a proteolytic cleavage 
performed by a host or pathogen protease at a region between two cysteine residues. The 
cleavage results in a di-chain toxin molecule with the protomer A and B linked by a disulphide 
bond. Some toxins, such as anthrax toxin, diphtheria toxin, and Clostridial neurotoxins traffic 
to vesicular compartments, where acidification triggers conformational change on the B 
protomer that forms a protein conductive channel/pore on the membrane through which it 
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translocates A protomer. Instead, other A-B toxins, including shiga toxin, cholera toxin, 
exotoxin A will travel through a different transport pathway to arrive at the ER. In either of 
these two intracellular schemes, it is presumed that the interchain disulphide that links A and 
B protomer must be cleaved before the translocation of A protomer into the cytosol (Figure 
1). While the mechanism of disulfide reduction-dependent translocation is not fully 
understood, and may be toxin-specific, there are several evidences that cellular redox factors 
play essential roles in toxin translocation.  My project has been focused on the important 
human pathogens that are A-B toxins: diphtheria toxin, tetanus and botulinum neurotoxins 
the etiologic agents of diphtheria, tetanus and botulism, respectively. 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Molecular organization and translocation of A-B toxins. Based on molecular organization and sites of 
membrane translocation, A-B toxins are divided into four groups. Group 1: the toxins are produced as a single 
polypeptide chain. Activation required proteolytic cleavage to generate two single polypeptide chains linked together 
by a disulfide bridge. Group 2: the protomers A and B are produced as separates proteins. The B protomer is 
activated by proteolytic cleavage and assembles into a heptameric complex that recruits the A protomer. There is no 
disufide bridge. Group 3: the proteolytic cleavage occurs in the A protomer, resulting in two fragments, A1 and A2 
that are linked by a disulphide bridge. Group 4: the toxins share a similar structure organization with the toxins in 
Group 1, but translocation occurs in the ER (Sun, 2012).  
 
2. Diphtheria toxin structure and mechanism of action 
Many bacterial toxins enter the cells via the endosomal pathway, in response to acidification 
as a key step of infection (Senzel et al., 1998). Diphtheria toxin (DT) is an A-B toxin released 
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by toxigenic strains of Corynobacterium diphtheria. DT is secreted as a single polypeptide 
chain of 535 residues (58 kDa), and activated by a proteolytic cleavage that is catalysed by 
the cellular protease furin. The resulting fragments (DT-A 21 kDa and DT-B 30 kDa) remain 
attached via non-covalent interactions and a single interchain S-S bridge. The first step of DT 
cell intoxication is binding to a cell surface receptor mediated by the C-terminal domain of 
DT-B (Collier, 2001; Murphy, 2011). Binding triggers the endocytosis of DT inside endosomes, 
which become rapidly acidic following the operation of a vacuolar- type ATPase proton pump 
(Houtari et al., 2011). The low pH triggers a structural change in DT that leads to the delivery 
of DT-A into the cytosol assisted by DT-B which inserts into the membrane forming a trans-
membrane ion channel (Oh et al., 1999). Cytosolic chaperons assist the refolding of DT-A on 
the cytosolic side of endosomal membrane. DT-A is then released in the cytosol upon reduc-
tion of the interchain disulphide bridge, which is the rate-limiting step of the entire process 
of cell entry. In the cytosol, DT-A  catalyses the transfer of ADP-ribose from NAD to the elon-
gation factor 2, causing its inactivation and the ensuing blockade of protein synthesis and cell 
death (Murphy, 2011). The protein monomer consists of three domains, organized to form a 
Y-shaped structure: i) the catalytic or C domain at the N-terminus, corresponding to frag-
ment A, characterized by an α + β fold, ii) a β-barrel jelly-roll-like receptor or R domain at the 
C-terminus, and iii) a central α-helical domain, called T domain which is the portion of DT-B 
that inserts into the lipid bilayer upon acidification, and assists the delivery of the catalytic 
domain into the cytosol (Sandvig et al., 1980; Collier, 2001). The exact molecular mechanism 
of membrane translocation mediated by the T domain is not well understood, but it is clear 
that the central issue is a membrane mediated refolding process. The structure of soluble T-
domain at neutral pH is known, but little structural information is available for membrane-
associated protein. 
 
3. Clostridial neurotoxins 
Tetanus (TeNT) and Botulinum neurotoxins (BoNTs) are A-B toxins that cause tetanus and 
botulism, respectively. Nine neurotoxins endowed with a metalloprotease activity have been 
characterized so far and are produced by neurotoxigenic anaerobic spore forming bacteria 
Clostridium: tetanus neurotoxin from Clostridium tetani and eight distinct serotypes of 
botulinum neurotoxins (BoNT/A to H) produced by strains or Clostridium botulinum or Clos-
tridium barati and Clostridium butirycum (Schiavo et al., 2000). They are the most potent tox-
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ins yet known, with an estimated lethal dose for humans around 1 ng/Kg of body weight 
(Gill, 1982). Both neurotoxins are characterized by a remarkable neurospecificity and their 
catalytic cleavage at low concentrations of neuronal substrates. The main difference be-
tween these toxins is in the intensity and duration of muscle paralysis. Tetanus is character-
ized by violent and spasms of the head, trunk and limb muscle, resulting in spastic paralysis. 
Indeed, botulism is characterized by flaccid paralysis of both skeletal and autonomic nerve 
terminals (Johnson, 1999).  
 
3.1 Tetanus neurotoxin 
The infectious nature of tetanus toxin have been known since the very beginning of medical 
literature. It was Hippocrates (year 358) who described the symptoms of a paralysed patient 
with hypercontracted skeletal muscle (Major, 1945). He termed such a spastic paralysis 
tetanus, that in greek means contraction. Often, tetanus is fatal. Death follows body 
exhaustion and occurs by respiratory or heart failure. Tetanus still takes hundreds of 
thousands of lives per year, and is major cause of neonatal death in nonvaccinated areas. The 
bacterium Clostridium tetani is strictly anaerobic, it does not possess the redox enzymes 
necessary to reduce oxygen. The presence of the bacteria does not cause the disease but 
instead the toxins it produces cause the disease state. It is widespread in nature in forms of 
spores, that germinate under appropriate condition of very low oxygen, slight acidity and 
availability of nutrients (Popoff, 1995). Such conditions are present in anaerobic wounds and 
skin ruptures where spores can germinate, produce a protein toxin in the bacterial cytosol 
that is released by autolysis. C. tetani produces two toxins; tetanospasmin and tetanolysin. 
Tetanolysin is a cytolysin that increases the permeability of cellular membranes through cell 
lysis (Hatheway, 1995). Tetanospasmin is the cause of tetanus and is sometimes referred to as 
tetanus neurotoxin (TeNT), as it acts on the central nervous system. The toxin binds 
specifically to peripheral motoneuron nerve terminals at the neuromuscular junction (NMJ) 
and enters inside as yet uncharacterized vesicles. It is retroaxonally drived and discharged 
into the intersynaptic space formed with the inhibitory neurons of the spinal cord, which 
ensure the balance contraction of opposing skeletal muscle. Tetanus neurotoxin then binds to 
presynaptic receptors of these neurons and is endocytosed inside synaptic vesicles 
wherefrom the A protomer enters the cytosol thanks to the B protomer, which, at low pH 
forms a transmembrane protein-conducting channel. Once inside the cytosol, the tetanus A 
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protomer displays its metalloproteolytic activity, that is specific for the integral protein of the 
synaptic vesicles membrane termed VAMP (vesicle-associated membrane protein). VAMP is 
cleaved and can no more form a complex (the SNARE complex) with SNAP-25 and syntaxin 
proteins of the cytosol face of the presynaptic membrane. The consequence is that no 
neurotransmitter is released and  the synapse of the inhibitory circuit is blocked, resulting in 
spastic paralysis (Montecucco et al., 2014).  
   
3.2 Botulinum neurotoxins 
Botulism was recognised and described much more later than tetanus. This later recognition 
is attributed to the much less evident symptoms to those of tetanus. In fact, botulism is 
characterised by a general muscle weakness, that affect ocular and throat muscles and then 
extends to the whole skeleton. In more severe cases, the flaccid paralysis is accompanied by 
impairment of respiration and of autonomic functions, and death may result from respiratory 
failure (Hatheway, 1995). Botulism is caused by intoxication with one of the eight distinct 
serotypes of BoNTs, indicated with letter from A to H, based on the fact that a serum raised 
against one toxin was not able to neutralise the others (Rummel, 2015). The spores of the 
different BoNTs germinate under different conditions, and the bacteria differ for nutrient and 
temperature requirements.  These differences in growth conditions explain why, contrary to 
tetanus, botulism is very rare in wound infections. Usually, a BoNT is introduced by eating 
foods contaminated by spores of Clostridium botulinum, which are preserved under 
anaerobic conditions that favor germination, proliferation and toxin production (Hatheway, 
1995). BoNTs bind to one of the several polysiaganglioside molecules, enriched in the 
presynaptic membrane at the NMJ and then to one protein of synaptic vesicles. BoNTs are 
then internalized inside the synaptic vesicles wherefrom the A protomer, a zinc 
metalloprotease, translocates into the cytosol assisted by B protomer, which forms a 
translocating channel following acidification of the synaptic vesicle lumen. The potency of 
botulinum neurotoxins is the result of an elaborate and efficient molecular mechanism of 
action, that impairs an essential physiological function: the neurotransmission at peripheral 
nerve terminals (Pantano et al., 2013). Once inside the cytosol the A protomer of BoNT/A/C/E 
cleave SNAP-25; the one of BoNT/B/D/F and G cleave VAMP; and the one of BoNT/C cleaves 
also syntaxin. So, the assembly of the nanomachine, that mediates fusion of synaptic vesicle 
membrane with release of neurotransmitter, is impaired and the synapse is paralysed 
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(Montecucco et al., 2014). BoNTs bind and act on the peripheral cholinergic nerve terminals, 
causing flaccid paralysis of both skeletal and autonomic nerve terminals (Pantano et al., 
2013).   
There are different vertebrates host of different BoNTs serotypes. BoNT/A/B, and E are those 
often related with human botulism, with fewer cases being caused by BoNT/F. Almost 
exclusively associated with botulism among birds is BoNT/C, whilst BoNT/D cause botulism in 
different animal species but not in humans. BoNT/E is more frequently associated with 
botulism of marine vertebrates and fish eating birds (Montecucco et al., 2015; Rossetto et al., 
2014). 
The main and life threating outcome arising from BoNTs action in vertebrates is the blockage 
of neurotransmitter release at the neuromuscular junction, which results in the impossibility 
of stimulating voluntary muscles and therefore a typical flaccid paralysis of botulism. In 
adults, botulism is generally caused by an intoxication through contaminated food with the 
toxin. Being that BoNTs are sensitive to proteolytic and denaturating conditions found in the 
stomach lumen. It is believed that to overcome this difficulty, they are produced as 
complexes with other nontoxic proteins, which enable a portion of BoNTs to reach the 
intestine undamaged. It is not an infection, since Clostridia colonization of the intestinal tract 
is quite difficult. This situation can happen in infants because ingested spores can germinate 
in the absence of competing resident microbiota (Rossetto et al., 2014). In this latter case 
BoNTs are produced and released in the intestine for prolonged periods of time causing 
infant botulism (Aureli et al., 1986; Koepke et al., 2008). There are three other rare forms of 
botulism (Figure 2): wound botulism that results from tissue contamination with spores, and  
is mainly associated with drug users; iatrogenic botulism which is due to the inappropriate 
administration or abuse of the toxin for cosmetic or therapeutic purpose; inhalational 
botulism, that is correlated to inhalation of BoNT-containing aerosols, and mainly associated 
to a possible use of BoNTs as bioweapon (Arnon et al., 2001). Despite the different forms, the 
symptoms of the disease are usually very similar. The facial and throat innervations are the 
first affected causing diplopia, ptosis and dysphagia. The paralysis continues and when 
respiratory muscles are involved, breathing is compromised and death comes through 
respiratory failure. However, since intoxicated nerves remain intact and do not degenerate, if 
mechanical ventilation is timely performed, patients survive fully recovering from the 
neuroparalysis, in a time window which depends on the amount of toxin poisoning nerve 
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terminals and on the BoNT serotype involved. The current therapy is aimed to neutralize 
circulating toxin using anti-BoNT serum and keep alive patients using artificial ventilation 
(Rossetto et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Different forms of human botulism. Until now, it has been characterized five forms of human botulism. 
The two most common forms are food-borne botulism, that occurs following the ingestion of BoNT-containing 
foods, and infant botulism, that is caused by the ingestion of food contaminated with spores that germinate in 
the gastrointestinal tract as a consequence of the lack of a mature microbiome. The other three forms are much 
rarer, they include inhalational botulism, iatrogenic botulism and, wound botulism. Following transcytosis across 
the intestinal epithelium and entry into the general circulation, the neurotoxin enters peripheral cholinergic 
nerve terminals, causing the flaccid paralysis. (From Rossetto  et al., 2014). 
 
4. Bacterial protein toxins in research and therapy 
Bacterial toxins were the first virulence factors discovered thank to their peculiar abilities. 
Since their discovery, they have played an essential role both in basic and applied research 
and in therapy and pharmaco-cosmetics. Many essential essential cell functions were 
discovered thanks to the toxins that could inhibit them: this was the case in studies of 
trafficking (e.g. clostridial neurotoxins) and of cytoskeleton actin organisation. Also, chimera 
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of toxins that bind specifically to cell surface receptors and are endocytosed (e.g. diphtheria 
toxin) can shuttle epitopes, nucleotides or peptides into cells. This use is particularly useful in 
developing therapeutical approaches against cancer. Diphtheria toxin has already been 
utilised as anti-cancer agent. Normally the targeting is achieved by deleting the receptor 
binding domain, and combining the remaining portion (translocation and catalytic domain) 
with proteins that selectively bind to the surface of cancer cells. 
Clostridial neurotoxins instead, have direct applications in therapy.  BoNTs can be considered 
Janus toxins, as they are the most deadly exotoxins known to humans and one of the safest 
drugs used in several human pathologies. Indeed, considering their relative ease of 
production and extremely potency, BoNTs are considered by the Center for Disease Control 
and Prevention (CDC) as category A agents, i.e. toxins that can be used as biological weapons, 
but, at the same time, for their neurospecificity and reversibility, they have become very 
useful therapeutics for a growing and heterogeneous number of human disease 
characterized by peripheral nerve terminals hyperactivity (Arnon et al., 2001). In addition, 
thanks to the comprehension of their molecular mechanism of action, BoNTs have become 
useful tools in the study of neuronal physiology. Botulinum neurotoxin (known as Botox) has 
also become a fashionable agent in cosmetic to efface wrinkles. 
 
5. Bacterial protein toxins studied in the present thesis 
During my Ph.D, I have studied the following bacterial protein toxins: diphtheria toxin, 
tetanus and botulinum neurotoxins from biochemical, structural and cell biology points of 
view. Below, I will briefly introduce the main projects I have worked. Detailed information 
about the toxins and the work done with them is given in the relative sections. 
In part I, I include an already published article in which I studied the conformational 
switching of diphtheria toxin at acidic pH. DT includes within its B protomer a T domain which 
is known to mediate the pH-dependent membrane translocation of A, by forming a channel 
through which the catalytic domain cross the endocytic vesicle membrane. I reported the 
first crystal structure of DT obtained in the presence of lipid bicelles (which simulate the 
endosomal membrane) and grown at pH 5.5, pH that mimics the acidic environment where 
translocation takes place. The crystal structure proposed throws lights in the initial event of 
the membrane translocation process. 
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In part II, I discuss a project which aimed to unravel the three dimensional structure of 
tetanus neurotoxin. To develop an effective structure-based vaccine/inhibitor/antitoxin to 
treat tetanus victims, an understanding of the molecular mechanism at the atomic level, is a 
prerequisite. Though experimental three-dimensional structures are available for the N-
terminal catalytic domain and C-terminal binding domain, no experimental structure is 
available of the entire TeNT molecule. I have performed several biochemical and structural 
studies to characterize the three dimensional structure of TeNT. Because TeNT is considered 
“uncrystallizable”, I focused on the use of antibody fragments (Fabs) as crystallization 
chaperons to aid the structural determination. Native gel analysis and size exclusion 
chromatography showed the formation of a stable complex in vitro between TeNT and the 
relative Fabs. Several crystallization experiments were carried out by high throughput 
crystallization screens. 
In part III, I show the work performed with the binding domains of several BoNT serotypes in 
order to study their trafficking at the neuromuscular junction. I present data of biochemical 
characterization of the recombinant binding domains, which are considered ideal tools for 
studying the initial trafficking events of BoNTs. The purified binding domains were used for in 
vitro and in vivo assays in order to test their functionality and their distribution along the 
neuromuscular junction (NMJ). The data from fluorescence analysis show high specificity of 
these binding domains at the NMJ, and a different staining between the several serotypes, 
reflecting their different time of intoxication, and perhaps a different pathway of trafficking. 
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Diphtheria toxin (DT), the etiological agent of the homonymous disease,
like other bacterial toxins, has to undergo a dramatic structural change in
order to be internalized into the cytosol, where it finally performs its func-
tion. The molecular mechanism of toxin transit across the membrane is not
well known, but the available experimental evidence indicates that one of
the three domains of the toxin, called the central a-helical domain, inserts
into the lipid bilayer, so favoring the translocation of the catalytic domain.
This process is driven by the acidic pH of the endosomal lumen. Here, we
describe the crystal structure of DT grown at acidic pH in the presence of
bicelles. We were unable to freeze the moment of DT insertion into the
lipid bilayer, but our crystal structure indicates that the low pH causes
the unfolding of the TH2, TH3 and TH4 a-helices. This event gives rise to
the exposure of a hydrophobic surface that includes the TH5 and TH8
a-helices, and the loop region connecting the TH8 and TH9 a-helices.
Their exposure is probably favored by the presence of lipid bilayers in the
crystallization solution, and they appear to be ready to insert into the
membrane.
Database
Coordinates and structure factors have been deposited in the Protein Data Bank under acces-
sion number 4OW6.
Introduction
Diphtheria toxin (DT) is a protein toxin that causes the
homonymous disease, which is currently re-emerging in
those areas of the world where vaccination programs
are not fully enforced [1]. DT has also been used to
prepare immune-conjugates aimed at deleting selective
populations of pathogenic cells [2]. DT is secreted from
Corynebacterium diphtheriae as a unique polypeptide
chain of 535 amino acids that is subsequently nicked
by proteases at a loop subtended by a single disulfide
bond. The resulting fragments (DT-A, 21 kDa; DT-B,
30 kDa) remain attached via noncovalent interactions
and a single interchain disulfide bridge. The first step
of DT cell intoxication is the binding to a cell surface
receptor mediated by the C-terminal domain of DT-B
[3,4]. Binding triggers the endocytosis of DT inside en-
dosomes, which become rapidly acidic following the
operation of a vacuolar-type ATPase proton pump [5].
The low pH triggers a structural change in DT that
leads to the delivery of DT-A into the cytosol. This
event is assisted by DT-B, which inserts into the mem-
brane and forms a transmembrane ion channel [6].
Cytosolic chaperones assist the refolding of DT-A on
Abbreviations
C domain, catalytic domain; DMPC, dimyristoyl phosphatidylcholine; DT, diphtheria toxin; PDB, protein data bank; R domain, b-barrel jelly-
roll-like receptor domain; T domain, central a-helical domain.
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the cytosolic side of the endosomal membrane [4,7–9].
DT-A is then released into the cytosol upon reduction
of the interchain disulfide bridge, which is the rate-
limiting step of the entire process of cell entry [10]. In
the cytosol, DT-A catalyzes the transfer of ADP-ribose
from NAD to elongation factor 2, causing its inactiva-
tion and the ensuing blockade of protein synthesis, and
eventually cell death [3].
DT is the prototype of bacterial exotoxins acting in
the host cell cytosol and consisting of two disulfide-
linked polypeptide chains [3,4,11,12]. Despite numerous
studies, membrane translocation is the least known step
of their cell intoxication mechanism [3,13]. The crystal
structure of DT has been determined in monomeric
and dimeric forms, with and without a nucleotide
bound [14–17], and in complex with an extracellular
fragment of heparin-binding epidermal growth factor
[18]. However, all crystals were grown at pH 7.5. The
protein monomer consists of three domains, organized
to form a Y-shaped structure: (a) the catalytic domain
(C domain) at the N-terminus, corresponding to frag-
ment A, characterized by an a + b-fold; (b) a b-barrel
jelly-roll-like receptor domain (R domain) at the
C-terminus; and (c) a central a-helical domain
(T domain), which is the portion of DT-B that is sup-
posed to insert into the lipid bilayer upon acidification,
and that assists the delivery of the C domain into the
cytosol [3,19,20]. It is noteworthy that the protein in
the crystal can be present as a monomer or as a dimer,
and a very intriguing example of domain swapping was
observed in the dimeric form [21]. This dimerization
was attributed to the buffer used and to a pH drop that
occurred during storage of the protein at low tempera-
ture. In any case, the active form of the toxin is consid-
ered to be the monomer.
Despite the large body of indirect evidence gathered
in the last 20 years on the DT-A low pH-driven mem-
brane translocation [4,6,12,22–27], its molecular
aspects remain elusive. The T domain comprises nine
a-helices (Fig. 1), and it appears to have been estab-
lished that the helical hairpin formed by the two
strongly hydrophobic TH8 and TH9 a-helices inserts
perpendicularly into the lipid bilayer. In order to allow
the insertion of such helices inside the membrane, the
T domain must undergo a large structural change, and
there is evidence that membrane lipids do play a role
in the process [12]. No structural data are available on
the ion channel formed by the T domain, and nor is it
known whether it is monomeric or oligomeric [28].
To obtain crystals of membrane proteins, bicelles
composed of portions of lipid bilayers and detergents
have been successfully introduced [29]. In an attempt
to clarify the membrane translocation mechanism of
DT, we have performed crystallization tests of DT at
acid pH and in the presence of bicelles. At variance
with other studies on the effect of pH on DT, where
the isolated T domain was employed, in this work we
used the entire toxin.
We report here the structure obtained at acidic pH,
which reveals a relevant initial molecular event of the
process.
Results and Discussion
The crystal structure of DT at acidic pH
Crystals of DT at the pH values present inside endo-
somes and in the presence of bicelles [dimyristoyl
phosphatidylcholine (DMPC)/CHAPSO] grow as long
and thin needles. They generally produce a fiber-like
spectrum (Fig. S1), suggesting that the presence of
bicelles and the low pH favor a conformational
change of the protein structure that gives rise to a
fibrous arrangement. However, in few cases and
using a microfocus beam (10–20 lm), we were able
to obtain a diffraction spectrum with defined Bragg
peaks. The best of them resulted in a diffraction
dataset at 2.8-A resolution, but, despite the modest
quality of the data obtained (Table 1), the structure
could be solved by molecular replacement, and the
molecular model was refined. The polypeptide chain
could be traced from residues 1 to 535, with the
exception of residues 188–199 and 221–266 (in
chain B, from 221 to 255). The two monomers pres-
Fig. 1. Structure of the T domain of DT with a-helices labeled.
Coordinates are from PDB 1MDT [15]). The three a-helices that
undergo unfolding at acidic pH are colored orange; the other a-
helices are shown in different colors for clarity.
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ent in the asymmetric unit (Fig. 2) are essentially
identical (the rmsd between all Ca atoms is 0.73 A),
with the exception of a flexible region corresponding
to a large portion of the TH4 a-helix (see next para-
graph). The only other significant difference is repre-
sented by loop 516–522, belonging to the R domain
and involved in contacts with the other monomer in
the crystal. The overall folding of the DT monomer
at acidic pH corresponds to that of the monomer at
neutral pH [15], with its three domains, C, T, and
R, organized in a Y-shaped structure (Fig. 3). At
acidic pH, the entire T domain shows higher overall
B-factors than the cores of the other two domains,
and several loops of the R domain also appear to be
quite flexible.
Comparison with DT at neutral pH
The cell parameters of our crystal are similar to those
of the crystal form of the orthorhombic monomeric
DT [Protein Data Bank (PDB) 1MDT [15]]. In partic-
ular, the two long cell parameters become significantly
longer (141.3 A versus 135.5 A; 176.0 A versus
168.5 A), whereas the shorter one remains the same
(47.4 A versus 47.0 A); this suggests that protonation
induces some repulsion between symmetry-related mol-
ecules. In addition, the neutral pH structure crystalliz-
es in space group P21212, whereas our crystals belong
to space group P212121. A comparison between the
final molecular models shows that the noncrystallo-
graphic two-fold axis that relates the two monomers
present in our asymmetric unit corresponds to the
Table 1. Data collection and refinement statistics.
Wavelength (A) 0.87290
Space group P212121
Cell dimensions
a, b, c (A), Z a = 47.44, b = 141.28, c = 176.02, Z = 2
Resolution (A) 47.44–2.80 (2.95–2.80)a
Rmerge 0.192 (0.683)
Rpim 0.088 (0.323)
<I/r(I)> 7.1 (2.7)
Completeness (%) 94.7 (98.2)
Multiplicity 5.5 (5.0)
Refinement
No. of reflections 28 350
Rwork/Rfree 0.238/0.322
No. of protein atoms 7374
Rmsd
Bond lengths (A) 0.01
Bond angles (°) 1.51
Ramachandran plot (%)
Most favored 85.3
Additionally allowed 13.5
Generously allowed 1.0
Disallowed regions 0.2
Overall G-factor – 0.1
aValues in parentheses refer to the last resolution shell.
A B
Fig. 2. (A) Cartoon view of the two
monomers of DT present in the
asymmetric unit. The C domain, T domain
and R domain are colored green, cyan,
and orange, respectively. A
noncrystallographic two-fold axis runs
approximately perpendicular to the plane
of the paper, in the center of the image.
(B) Same as (A), but showing the surface
of the two molecules.
A B
Fig. 3. Crystal structure of the monomer of DT at low pH. (A)
Cartoon view of the DT monomer. The C domain is colored green,
the T domain cyan, and the R domain orange. (B) Same as (A),
except that the diameter of the tube is proportional to the thermal
B-factor of the atoms of each residue. The most flexible parts
(excluding the TH2, TH3 and TH4a-helices, which are not visible in
the structure) are the loops of the R domain; the b-sheets of this
domain are quite rigid, as are all residues of the C domain. The
entire T domain appears to be more flexible than the cores of the
other two domains.
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crystallographic two-fold axis of space group P21212.
In fact, molecules are packed in the crystal cell in two
layers, roughly parallel, in our reference system, with
the crystallographic ac-plane. The change of pH has
no effect on the packing of the molecules in each layer,
but it causes a shift of one layer with respect to the
other in the c-direction (Fig. 4).
The structure of DT monomer at acidic pH is compa-
rable to that at pH 7.5: the rmsd between equivalent Ca
atoms is 0.90 A for monomer A and 1.0 A for mono-
mer B (477 and 488 residues compared, PDB 1MDT
[15]). However, a very significant difference in the struc-
ture adopted by DT at acidic pH in the presence of bi-
celles is the unfolding of three a-helices, TH2, TH3, and
partially TH4, located at the bottom of the Y-structure
of DT (in red in Fig. 5). In particular, in monomer B,
the electron density for the TH2 and TH3 helices is
totally absent, whereas the TH4 a-helix is partially
unfolded. In monomer A, all three a-helices, TH2,
TH3, and TH4, are absent, and the main chain restarts
at residue 276. Other differences can be observed in the
R domain, in the loop regions 407–413, 463–469, and
516–522, and from residues 494 to 507 (Fig. 5). In con-
trast, the structure of the catalytic domain is well pre-
served. Given that all available evidence indicates that
unfolding of DT-A is implicated in its translocation
across the lipid bilayer, our finding may suggest that the
present structure represents an initial event in the pro-
cess of the low pH-driven membrane insertion of DT.
Mechanisms of the conformational switch
Different mechanisms have been proposed for the con-
formational switching of DT triggered by acidic pH.
They emerged from experiments generally performed
with the isolated T domain and in the presence of lipid
bilayers. Scanning mutagenesis and nitroxide derivati-
zation experiments indicated that the TH8 a-helix and
loop TL5 can insert into the bilayer [6], whereas heavy
chemical modifications with a hexahistidine tag and
biotin indicate the presence in the bilayer of three
membrane-spanning segments, TH5, TH8, and TH9
B
A
Fig. 4. Stereo view of the packing
superposition of DT at acidic pH (cyan) and
at neutral pH (orange). Molecules are
packed in the cell in two layers, labeled A
and B (the reference system is that of our
crystal cell, so that the b-axis and the c-
axis run in the plane of the paper in the
vertical and horizontal directions,
respectively). In layer A, only the two
molecules present in the asymmetric unit
are shown. When the molecules of the
P21212 space group [15] are superposed
on layer A, molecules of layer B are
shifted along the c-direction.
Fig. 5. Superposition of the Ca chain trace of the DT monomer at
neutral and low pH. The C domain, R domain and T domain of DT
at low pH are colored green, cyan, and orange, respectively, and
the structure at neutral pH (PDB 1MDT) is colored yellow, with the
exception of the TH2, TH3 and TH4 a-helices, which are colored
red.
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[22]. With a similar approach of chemical biotinylation
of mutated residues, the TH5, TH6, TH7, TH8 and
TH9 a-helices were found to be inserted into the mem-
brane [23], and this model is also supported by fluores-
cence quenching experiments [26]. Experiments using
the hydrophobic photoactivable reagent diamonofluor-
escein showed the TH1, TH8 and TH9 a-helices to be
inserted into the hydrophobic core of the lipid bilayer
[24]. A more comprehensive approach combining fluo-
rescence spectroscopy with extensive molecular dynam-
ics [30] suggests that the first step of the
conformational transition is represented by the partial
loss of the TH1 and TH2 helical structure, an event
that allows the exposure of the hairpin formed by the
TH8 and TH9 a-helices and their access to the mem-
brane. At variance with this, the present structure indi-
cates that the first portion of the T domain to unfold
comprises the TH2, TH3 and partially the TH4 a-heli-
ces (Fig. 5). The present work is in agreement with the
recent indication that a key event in the destabilization
of the conformation of the T domain is the proton-
ation of two histidines: His257 located at the end of
the TH3 a-helix, and His223, located in the loop con-
necting the TH1 and TH2 a-helices [27, 37]. This loop
was suggested to act as a safety latch, by modulating
the protonation of His257 and preventing premature
unfolding [12]. The side chains of the two histidines
face each other, and their protonation is likely to
induce a repulsion that destabilizes the TH2–TH3 hair-
pin, thus causing the disordering of both helices. The
disordered area is heavily charged, as it contains seven
lysines and nine glutamates, but they are probably
unaffected at pH 6.
The unfolding of the TH2, TH3 and TH4 a-helices
exposes a hydrophobic surface (Fig. 6), which includes
the TH5 and TH8 a-helices and the loop region connect-
ing the TH8 and TH9 a-helices. The latter area, in fact,
shows some differences from the structure of DT at neu-
tral pH. It must be stressed that our crystals were grown
in the presence of bicelles and, notably, the same crys-
tals were not obtained without bicelles at the same pH
value. Despite the fact that crystals did not grow inside
the bicelles, it is reasonable to consider that the presence
of lipids stabilizes the hydrophobic surface generated by
the unfolding of the TH2, TH3 and TH4 a-helices. It is
therefore safe to speculate that our structure may well
represent the first molecular event in the low pH-driven
process of the membrane insertion of DT-B.
Conclusions
The present article describes the first structure of the
entire DT molecule grown in the presence of lipidic
bicelles that mimic the membrane. It sheds light on the
first molecular events in the complex process of mem-
brane insertion of DT, with translocation of its
C domain. In fact, it indicates that the first part of the
molecule to change structure following protonation
includes the TH2 and TH3 a-helices at the bottom of
the molecule, which would uncover a hydrophobic
region, and the TH4 a-helix, which is located in a
region critical for the interaction between the
T domain and the receptor-binding domain. This
region includes several high-pKa carboxylate residues
involved in the formation of salt bridges with a group
of cationic residues.
Experimental procedures
Crystallization
DT was purified and nicked as described previously [10].
The toxin was dialyzed overnight against 50 mM NaCl and
100 mM Na3C6H5O7 (pH 7.2), and its final concentration
was adjusted to 5 mgmL1. Bicelles were prepared by mix-
ing appropriate amounts of DMPC and CHAPSO to reach
a DMPC/CHAPSO molar ratio of 2.8 : 1. After the compo-
nents had been mixed, an aqueous solution was added in
A B
Fig. 6. Qualitative electrostatic potential
surface of the entire DT monomer at
neutral pH (A) and of the DT monomer at
low pH (B). The view is rotated, with
respect to Fig. 5, by ~ 90° along a
horizontal axis. In (A), the hydrophilic
surface is mainly formed by the TH2 and
TH3 a-helices, whereas the hydrophobic
portion exposed in (B) is mostly formed by
the TH5 and TH8 a-helices.
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order to reach a total lipid concentration of 40% (w/v).
Bicellar suspensions were prepared by several cycles of
ultrasonic dispersion at 52 °C in a bath-type sonicator (Falc
Instruments, Treviglio, Italy), and freezing until the samples
became transparent. Bicelles were then mixed with the pro-
tein at a protein/bicelle ration of 4 : 1 (v/v). The pH of the
DT/bicelle mixture was lowered by dialysis at room temper-
ature, with a Slide-A-Lyser dialysis cassette (Fermentas,
Thermo Fischer Scientific, Vilnius, Lithuania), with a 2-kDa
cut-off, and 2 M HCl being added to the medium drop by
drop until a pH of 5, 6.0 or 6.5 was achieved. These pH val-
ues were chosen because they are estimated to be present in
the endosomal lumen or close to the luminal surface of the
endosomal membrane. Crystals were obtained at 20 °C with
the hanging drop method by mixing 2 lL of the protein/bi-
celle mixture with 1 lL or 2 lL of precipitant solution con-
taining 0.1 M sodium chloride, 0.1 M magnesium chloride,
0.1 M Hepes (pH 8) and 11% w/v poly(ethylene gly-
col) 1500 (solution C9 MemGold HT-96; Molecular Dimen-
sions Ltd., Newmarket, Suffolk, UK) or 0.2 M magnesium
chloride, 0.1 M Tris/HCl (pH 8.5), and 25% w/v poly(ethyl-
ene glycol) 4000 (solution E6).
Structure determination and refinement
A large number of crystals, > 45, were mounted and tested
at the ID23-2 microfocus beamline of the European Syn-
chrotron Radiation Facility (Grenoble, France) or at the
PXII beamline of the Synchrotron Light Source of the PSI
facility in Villigen (Zurich, Switzerland). They generally
showed a fiber-like diffraction spectrum, with axial reflec-
tions corresponding to a repetition period of ~ 43 A. The
use of only a few crystals gave rise to a spectrum with
Bragg peaks in some orientations, and in a few cases it was
possible to obtain a complete diffraction dataset. The best
native dataset, diffracting at 2.8-A maximum resolution,
was measured from a crystal grown from solution E6. The
final pH of the drop in this condition was 6. Data were
indexed and integrated with XDS [31] and merged and scaled
with SCALA [32]. Crystals belong to the orthorhombic space
group P212121, with the following unit cell dimensions:
a = 44.74 A, b = 141.28 A, and c = 176.02 A. Two mono-
mers are present in the asymmetric unit, corresponding to a
VM of 2.45 A
3/Da and an approximate solvent content of
50%. The structure was solved by molecular replacement
with the structure of monomeric DT (PDB 1MDT [15]) as
the template, by use of MOLREP contained in the CCP4 crys-
tallographic package [33]. The model was manually
adjusted with COOT [34]. Refinement was carried with PHE-
NIX [35]. The final crystallographic R-factor is 0.238
(Rfree = 0.322). Owing to the low resolution, no solvent
molecules were added. The relatively high R-factor is justi-
fied by the very small crystal sizes and their low diffraction
power, as also indicated by the high Rmerge value. The elec-
tron density map is quite good (Fig. 7). Geometrical
parameters of the models, checked with PROCHECK [36], are
generally better than expected for this resolution. Data col-
lection and refinement statistics are summarized in Table 1.
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PART II: STRUCTURAL CHARACTERIZATION OF TETANUS NEUROTOXIN USING 
ANTIBODY FRAGMENTS AS TOOLS FOR THE CRYSTALLIZATION 
 
1. INTRODUCTION 
1.1 Molecular structure and properties of tetanus neurotoxin 
Tetanus neurotoxin (TeNT) acts on the central nervous system by inhibiting neurotransmitter 
release and causing spastic paralysis. TeNT binds to peripheral neuronal synapses, is 
internalized and moves by retrograde transport up the axon into the spinal cord where it can 
move between postsynaptic and presynaptic neurons. It is produced by Clostridium tetani  
but shares 65 % sequence homology and 35% identity with BoNT serotypes. TeNT is a single 
polypeptide of 1315 aminoacids residues, approximately of 150 kDa. The toxin is composed 
of a heavy chain (HC) and a light chain (LC) linked together by a disulphide bond. The binding 
and the translocation domains are located in the heavy chain, whereas the catalytic domain 
resides in the light chain of the molecule (Johnson, 1999; Pellizari et al., 1999). It is a zinc 
metalloproteases, Zn2+ dependent, and heavy-metal chelators generate inactive apo- 
neurotoxin. TeNT cleaves VAMP, at an identical site cleaved by BoNT/B (Schiavo et al., 1992; 
Schiavo et al., 1992; Lalli et al., 1999). 
 
 
 
 
 
Fig. 2.1: Domain organization of Tetanus neurotoxin. Every of that encompasses a specific role in cell 
mechanism of intoxication: the Hc domain binds specifically to nerve terminals; the HN domain translocate the L 
chain into the nerve terminal cytosol; and L chain is a metalloprotease that cleaves and inactivates specific 
SNARE proteins that are involved in neurotransmitter release, thereby causing neuroparalysis (Adapted from 
Pellizari et al., 1999). 
 
The two chains, based on their functionality properties, can be divided into three domains 
(Fig. 2.1): (I) Hc (50 kDa, in green) is involved in nerve terminal binding and internalization; (ii) 
HN (50 kDa, in yellow), assists the translocation of the catalytic part of the toxin from the 
Lc HN HC 
Light Chain (LC) Heavy Chain (HC) 
N C 
Catalytic domain Translocation domain Binding domain 
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internal part of mature endosomes into the neuronal cytosol; (iii) the Lc, catalytic domain (50 
kDa, in red) is a metalloprotease that cleaves the SNARE proteins interfering with the release 
of neurotransmitters that results in a reversible neuroparalysis. Despite the amino acid 
sequence variability among the Clostridial neurotoxins variants, the structure organization is 
however maintained, as it mechanism of nerve intoxication (Schiavo et al., 1992). 
The early step in tetanus toxin internalization is cell binding, that is mediated by the receptor 
binding domain (Hc). The structure of the recombinant 50 kDa Hc has been solved by X-ray 
crystallography and it showed that it was structurally similar to the BoNTs binding domain 
(Emsley et al., 2000; Fotinou et al., 2001). It is organised in two subdomains: an amino-
terminal lectin-like jelly-roll subdomain (HCN, residues 865- 1110) and a carboxyl-terminal 
beta-trefoil subdomain (HCC, residues 1110-1315) linked by a single chain. Each of these 
subdomains is composed of beta-sheets joined by loops that protrude from the molecule 
(Fig. 2.2, A). In particular, the beta-trefoil subdomain (HCC) seems to have a relevant role in 
ganglioside binding than does the amino-terminal lectin like subdomain, which was 
demonstrated by analyzing the localization of these binding domain. Instead, it is still unclear 
that  what role  plays the HCN domain during intoxication. Several hypothesis suggest a 
function as a rigid, complex spacer between HN and HCC- domain as well as an involvement in 
the translocation process (Brunger and Rummel, 2009). 
Gangliosides are in the category of glycosphingolipids that are found predominately in 
neuronal tissues. They consist of sialic acid linked to a sugar (glucose, galactose, GalNAc, 
GlcNAc and/or fructose) backbone attached to a ceramide base. Gangliosides make up 
approximately 10% of a neuron’s total lipid content and they have function in cell signal 
transduction. Hc of tetanus toxin preferentially binds to the gangliosides, in particular the 
GT1b (Mocchinetti, 2005). A synthetic analogue of the GT1-b ganglioside was made in order 
to increase solubility because a crystal structure of the Hc and native GT1-b could not be 
obtained (Fotinou et al., 2001). Through binding studies it was also shown that the aminoacid 
residues tryptophan 1288, histidine 1270 and aspartate 1221 are critical for the binding of Hc 
to ganglioside GT1b (Louch et al., 2002). Although the affinity of Hc for gangliosides has been 
widely characterized, another hypothesis suggest that a high affinity receptor is involved in 
TeNT binding and internalization. Schiavo and co-workers proposed and demonstrated that a 
15 kDa  surface glycoprotein interacts with tetanus toxin in neuronal cell lines and motor 
neuron (Bercsenyi et al., 2014). The same group has also suggested that a GPI anchored 
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protein Thy-1 can interact with tetanus toxin to mimic ganglioside binding (Herreros et al., 
2001). In addition, After internalization into the motor neuron membrane TeNT is transported via 
retrograde axonal transport and so reach the central nervous system. 
 
                               
               
 
 
 
 
      
Fig. 2.2: Crystal structures of Hc-TeNT and Lc-TeNT. (A) Crystal structure of TeNT binding domain complexed 
with a synthetic GT1b analogue, PDB 1FV2. (B) Crystal structure of TeNT light chain, PDB 1Z7H. 
 
After cell binding and internalisation into neuronal cells, the toxin is translocated from 
mature endosomes into neuronal cytoplasm. TeNT can form channels in lipid membranes 
when a structural change in its translocation domain is induced by the acidification of the 
endosomal environment (Sheridan, 1998). The translocation domain fold is markedly 
different from the folds observed in other toxins that undergo pore formation and 
translocation (Lacy and Stevens, 1998). It occludes access to a large, negatively charged cleft 
leading into the active-site zinc ion of the catalytic domain. The translocation domain is able 
to form channel in artificial bilayers (Blaustein et al., 1987) visualized through electron 
cryomicroscopy. A requisition for the channel formation seems to be the oligomerization of 
four the amphipathic alpha-helices of the translocation domain. But, to date there is no 
molecular mechanism, by which pH triggers the translocation domain to change structure 
and form a membrane-spanning channel.  
Experimental three-dimensional structure is available also for the N-terminal catalytic 
domain of tetanus toxin (Breidenbach MA and Brunger, 2005; Rao et al., 2005; Fig. 2.2, B). 
The overall structure of TeNT-LC is similar to the other known CNT light chain structures. 
Differences between TeNT-LC and the other CNT light chains are mainly limited to surface 
features such as unique electrostatic potential profiles. The catalytic domain shares 51,6% 
sequence identity with Botulinum neurotoxin type B. It contains the HEXXH motif, typical of 
many zinc proteases. Other than this motif, the catalytic domain shares no sequence 
A B 
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similarity with proteins outside the Clostridial family. The TeNT-Lc crystallographic structure 
shows the active site located deep inside a cavity by which the substrate gains access to the 
active site. The active site is centered around a zinc cation directly coordinated by residues 
His232, His 236 and Glu270 (Rao et al., 2005).  
Considering that several complete crystallographic structures of BoNTs (BoNT/A, Lacy et al., 
1998; BoNT/B, Swaminathan et al., 2000; BoNT/E, Kumaran et al., 2009) are available, there is 
no complete crystallographic structure for TeNT, although the high sequence similarity, the 
same domain organization and mechanism of action, between the above Clostridial neuro-
toxins. Unraveling the three dimensional structure of TeNT could provide valuable infor-
mation about the molecular mechanism of membrane translocation, a step which is still un-
clear not only for TeNT but also for all the BoNT serotypes. TeNT is also among the most poi-
sonous substances on Earth and major cause of neonatal death in non-vaccinated areas. 
Chemically modified TeNT with formaldehyde, is the most used human vaccine. However, it is 
believed that genetically modified toxin better preserve immunogenicity than chemical modi-
fication. To develop an effective structure-based vaccine/inhibitor/antitoxin to treat tetanus 
victims, an understanding of the molecular mechanism at the atomic level, is a prerequisite. 
So the aim of this project was the structural investigation of TeNT through crystallization 
studies.  Because TeNT is considered “uncrystallizable” I focused on the use of antibody frag-
ments (Fabs) as crystallization chaperons to aid the structural determination. I determined 
the in vitro conditions for a complex formation between TeNT and the respective Fabs 
screened. I could obtain binary and ternary complexes, that were analysed in vitro for stabil-
ity and solubity, and in vivo tested for their protection ability against tetanus infection. The 
whole work was carried out in collaboration with Prof. Antonio Lanzavecchia at IBR, 
Bellinzona, Switzerland; and with Prof. Giuseppe Zanotti at the Department of Biomedical 
Sciences, University of Padova, Italy. 
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2. MATERIAL AND METHODS 
Reagents and proteins. All chemicals used were from Sigma Aldrich. TeNT was previously 
isolated from culture filtrates of C.tetani strain Y-IV-3 (WS 15), frozen in liquid nitrogen and 
stored at -80°C in 10 mM Hepes-Na, 50 mM sodium chloride, pH 7.2. The human monoclonal 
antibody and the fragments derived from these antibodies (Fabs) were kindly gifted by prof. 
A. Lanzavecchia, IBR, Bellinzona, Switzerland.  
Determination of the binding sites of the human monoclonal antibody. Full-length TeNT and 
Hc-TeNT (a  kindly gift of Prof. T. Binz, Hannover, Germany)  were used for the determination 
of the binding site. 1ug of each was loaded onto 4-12% SDS-Page gel (ThermoFischer 
Scientific) and separated by electrophoresis in 1X MES buffer. Proteins were transfered onto 
Potran nitrocellulose membranes (Whatman) and saturated for 1 h in PBST (1X PBS with 0.1% 
Tween20). After saturation the nitrocellulose membranes were incubated with all the series 
of antibodies in order to identify their binding site. The membranes were then washed three 
times with PBST and incubated with a secondary anti human antibody-HRP conjugated. 
Finally, membranes were washed twice with PBST and one with PBS. Visualization was 
carried out using Luminata Crescendo (Merck Millipore). If both TeNT and TeNT-Hc will be 
visualized the binding site of the antibody is the binding domain. If will be visualized just 
TeNT  the binding site is the translocation domain, HN.  
Cerebellar Granule Neurons (CGN) cultures. Primary cultures of rat cerebellar granule neu-
rons (CGNs) were prepared from 6- to 8-days-old rats. Cerebella were isolated, mechanically 
disrupted and then trypsinized in the presence of DNase I. Cells were then plated into 24 well 
plates, pre-coated with poly-L-lysine (50 μg/mL), at a cell density of 4 x 105 cells per well. 
Cultures were maintained at 37 °C, 5% CO2, 95% humidity in BME supplemented with 10% 
fetal bovine serum, 25 mM KCl, 2 mM glutamine and 50 μg/mL gentamicin (indicated as 
complete culture medium). To arrest growth of non-neuronal cells, cytosine arabinoside (10 
μM) was added to the medium 18–24 h after plating.  
TeNT in vitro inhibition assay. TeNT was first incubated in reducing buffer (150mM NaCl, 
10mM NaH2PO4, 15mM DTT, pH 7.4) and in the presence of different concentrations of hu-
man monoclonal antibody, for 30min at 37°C. Then, CGNs at 6-8 days in vitro were treated 
with 1 nM TeNT in complete medium and left for 3.5  hours at 37 °C. For immunoblotting 
analysis, cells were directly lysed with reducing Laemmli sample buffer containing protease 
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inhibitors (complete Mini EDTA-free, Roche). Equal amounts of protein were loaded onto a 
4-12% NuPage gel. The inhibition of the proteolytic activity of TeNT was evaluated using a 
specific antibody against VAMP2 (Synaptic System, 104 211). 
Mouse lethality assay. All experiments were performed in accordance with the European 
Communities Council Directive n°2010/63/UE and approved by the Italian Ministry of Health. 
Lethality assays were performed using Swiss-Webster adult male CD1 mice weighing 26-28g. 
Mice were intraperitoneally injected  with 4pg/g TeNT, pre-incubated for 1h at room with the  
Fabs. Mice were monitored every day (for 1 week), after which the experiments was 
considered ended. Results are displayed as Kaplan-Meyer plots, and analysed with a Mantel-
Cox test for statistical significance. 
Native gel analysis and Size Exclusion Chromatography. In vitro reaction between TeNT and 
Fabs was done overnight at 4°C, stiring. The complex formed was visualized in 4-16% Native-
PAGE gel (ThermoFischer, Scientific) and purified from unbound Fab by gel filtration 
(Superdex 200 10/30, GE). 
Crystallization. Proteins, like many molecules, can be prompted to form crystals when placed 
in the appropriate conditions. In order to crystallize a protein, the purified protein undergoes 
slow precipitation from an aqueous solution. As a result, individual protein molecules align 
themselves in a repeating series of "unit cells" by adopting a consistent orientation. The 
importance of protein crystallization is that it serves as the basis for X-ray crystallography, 
wherein a crystallized protein is used to determine the protein’s three-dimensional structure 
via X-ray diffraction. The reason X-rays are used is that their wavelength range is of the same 
order of magnitude as chemical bonds, thus allowing obtaining an image with a resolution 
equivalent to interatomic distances (0.8–2.5 Å). Two of the most commonly used methods for 
protein crystallization fall under the category of vapor diffusion. These are known as the 
hanging drop and sitting drop methods. Both entail a droplet containing purified protein, 
buffer, and precipitant being allowed to equilibrate with a larger reservoir containing similar 
buffers and precipitants in higher concentrations. Initially, the droplet of protein solution 
contains an insufficient concentration of precipitant for crystallization, but as water vaporizes 
from the drop and transfers to the reservoir, the precipitant concentration increases to a level 
optimal for crystallization. Since the system is in equilibrium, these optimum conditions are 
maintained until the crystallization is complete.  
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Hanging drop: the drop, containing the protein and the precipitant, is placed on a silinized 
coverslip (which confers to the drop a semi spherical shape for a uniform evaporation), it is 
then inverted and used to seal the system. 
Sitting drop: the drop, containing the protein and the precipitant, is placed on a depression in 
a microbridge in the well. The system is sealed with an object slide or crystal clear tape. 
Many different crystallization trials with TeNT-104, TeNT-110 and TeNT-104-110 complexes 
were performed at both 4 and 20°C. The crystal plates were done using robotic system. The 
crystallization kits tested are the following: Jcsg Core I-IV, PACTscreen, PEGsSuite, The Classic 
Suite (Qiagen), JcsgPlus, Structure screen I-II, MemGold I and II, MemGold plus (Molecular 
Dimensiion). 
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3. RESULTS AND DISCUSSION 
In vitro screening of the human monoclonal antibodies (hu-mAb). Considering the three 
domain organization (Hc- binding domain; HN- translocation domain; LC-catalytic domain) of 
the TeNT, we first determined the binding sites of each hu-mAb. Through western blotting 
analysis and by using a secondary human antibody we blotted the heavy chain of TeNT (TeNT-
HC, 100kDa) and the recombinant binding domain of TeNT (TeNT-Hc, 50kDa). If from the 
western blotting are visualized both bands of TeNT-HC and TeNT-Hc the hu-mAb binds to the 
binding domain of the toxin. Instead if it is visualized only the band of TeNT-HC the antibody 
binds to the translocation domain of the toxin.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3: In vitro screening of human monoclonal antibody (hu-mAb) against TeNT. In the first column are 
shown the whole set of human monoclonal antibodies screened. The second column the concentration of each 
antibody. In the third column are shown the result from the western blotting analysis for the determination of 
the binding sites. In the fourth column are summarized the results from the in vitro inhibitory assays on CGNs. 
The fifth column shows the lower concentration at which the antibodies gives protection in vitro. 
Results are shown in Fig. 2.3, it summarizes the whole set of antibodies screened, their 
binding sites on TeNT and their inhibitory activity. The last one was evaluated by following 
25 
 
the inhibition of the proteolytic activity of TeNT on CGNs. The use of cultured cerebellum 
granular neurons offers a simple and rapid way to screen the efficacy of each hu-mAb in 
inhibiting TeNT activity. The incubation with 1nM TeNT induces the cleavage of VAMP2 and 
its truncated form is then visualized by western blotting, revealed with a specific antibody. 
only five antibodies, from the whole set tested prevents the proteolytic activity in a 
concentration dependent manner. From this group of five hu-mAb, TT104.14 and TT110 
resulted to be the best ones, giving a maximal protection at 2.5 nM and 0.5 nM, respectively. 
In vivo screening: mouse lethality assay of TeNT with hu-mAb TT104.14 and TT110. We 
further investigated the two hu-mAb, testing their inhibitory effect also in vivo. A wide range 
of doses from 2 pg/g to 20 pg/g was administered via intraperitoneal injections in mice. The 
antibodies were well tolerated by mice. The lethality of TeNT was evaluated in preliminary 
experiments, and a dose of 4 pg/g was sufficient to progressively induce classical symptoms 
of tetanus (generalized weakness, spasms limb muscle, labored breathing) and cause the 
deadly respiratory failure post injection. 
 
Fig. 2.4: Mouse lethality assay. The hu-mAbs tested delay and strongly protect mice against death induced by 
TeNT. Adult CD1 mice injected with 4pg/G TeNT, previously incubated with hu-mAbs at different ratios. For each 
condition n=9 mice were used. The animal were monitored every day. (A) The survival curve of hu-mAb TT104.4. 
(B) The survival curve of hu-mAb TT110. 
The traces of Figure 2.4 (panel A) show that hu-mAb TT104,14 against the binding domain 
completely blocks the TeNT proteolytic activity to at least 1:1 ratio. Instead, the hu-mAb 
TT110 specific to the translocation domain, completely block the TeNT action at 1:5 ratio. An 
explanation for such different ratio between the two antibodies could be that for blocking 
the toxin action at the step of translocation requires more antibody, because the toxin is 
already inserted into the membrane of the vesicular compartment.  
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In vitro binding of Fabs with TeNT, binary complex formation. Having established the in vitro 
and in vivo inhibitory activity of the two hu-mAbs, we focused on the antibody fragments 
(Fabs) of the two identified hu-mAbs. This, considering that the aim of my work was to 
perform structural studies on TeNT, by using “chaperon molecules” to aid structural 
determination. Native antibodies are not suitable for co-crystallization attemps. They have 
flexible linker regions connecting the variable and constant domains (Figure 2.5, A). 
Monovalent antibody can be generated by proteolytic cleavage of the whole antibody, 
producing the two Fab fragments per antibody molecule (Figure 2.5, B). Recombinant 
antibody fragments are more versatile. They can be obtained by cloning the encoding genes 
from hybridoma cell lines, as well as by direct selection of recombinant antibody fragments 
from phage display libraries or by ribosome display. Up to now, all antibody fragments 
successfully used from co-crystallization are derived from hybridoma cell lines. So, the 
approach utilized for the crystallization studies of TeNT was that of using the antibody 
fragments as tools for stabilizing functionally relevant states of the protein. A binder target-
protein complex has an enhanced chance to crystallize when a particular target protein 
conformation is stabilized. This is an approach very well supported in literature, in particular 
for membrane proteins, whose crystallization is quite difficult ( Hunte, 2002; Röthlisberger et 
al., 2004; Griffin and Lawson, 2011; Bukowska and Grütter, 2013).  
 
 
 
 
 
Fig. 2.5: Antibody scheme. An antibody molecule is composed by two heavy chains (H) of 50 kDa each, and two 
light chains (L) of 23 kDa each (A). Linked together by disulfide bonds and non-covalent interactions in a Y 
formation. Proteolytic cleavage of an antibody can produce two Fab fragments and a Fc fragment. 
We focused on the biochemical analysis of the complex formed between TeNT and Fabs, 
(Fab104.14 corresponding to the hu-mAb TT104.4; Fab110 corresponding to hu-mAb TT110). 
From preliminary experiments we found that the best conditions for an in vitro reaction are 
the following: molar ratio 1:1 (TeNT:Fabs),  incubation at 4°C overnight, stiring. The binary 
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complex formation was confirmed by a Native-PAGE analysis, which allows to detect proteins 
that retains their folded conformation (Figure 2.6). It is an excellent tool to detect binding 
events (protein-protein or protein- ligand). In our case we have a protein-protein interaction, 
that originates two binary complexes of 200kDa (TeNT-Fab104.14; TeNT-Fab110). The Native- 
PAGE analysis, clearly shows a molecular shift when TeNT and Fabs are putted together. 
Moreover, form the gel it seems that for the binary complex formation is necessary even less 
Fab, less than 1:1 molar ratio. Meanwhile the band of Fab110 is clearly evident in native gel, 
the one of Fab104.14 is not. This may be due to its intrinsic properties (charges and 
hydrodynamic size). But, the fact that a band corresponding to 200 kDa molecular weight is 
evident even when Fab104.14 is added, we conclude that also the binary complex TeNT-
Fab104.14 is formed.  
                
Fig. 2.6: Native-PAGE analysis of in vitro reactions between TeNT and Fabs.  In the first lane 5 ug of 
NativeMark
TM
  unstained protein standard (ThermoFischer Scientific); second lane 1 ug of TeNT, 150 kDa; third 
lane 1 ug of Fab110, 46 kDa; lanes  from 4 to 6, reactions of TeNT-Fab110 of three different molar ratios; 
seventh lane 1 ug Fab104.14, 46 kDa; lane from 8 to 10, reaction of TeNT-Fab104.14 of three different molar 
ratios. 
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Size exclusion chromatography (SEC) of the binary complexes. The fractions containing both 
binary complexes were pulled and concentrated until 500 µl, and subsequently loaded on 
Superdex 200 10/30 gel filtration column. This purification step has a triple function: it serves 
to remove the unbound Fabs, exploiting the difference in molecular weight, it allows us to 
see what is the state of our protein, whether aggregated or monodisperse. Furthermore, the 
gel filtration can determine whether the protein complex TeNT-Fab is  stable in solution since 
a stable complex elutes as a single peak containing the two species. As we can seen from the 
chromatogram there are two peaks (Figure 2.7, A and B): the main peak at 11 (or 11.5) 
elution volume and a second peak at 15 ml elution volume. Two samples corresponding to 
the first peak, and to the second were loaded onto SDS-PAGE gel to determine its 
composition. The gel shows that in the peak are present both TeNT and Fab, which firmly 
elute as a single molecular specie, instead in the second peak is present the unbound Fab. 
For the first time we see a TeNT-Fab complex non aggregated and we have a second evidence 
that the Fabs are able to directly interact with TeNT in vitro. A fraction from the first peak of 
each binary complex was also loaded onto NATIVE-PAGE gel to further confirm complex 
formation (Figure 2.7, C). 
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Considering that SEC separates molecules according to their differences in size, we could 
appreciate the molecular shift from TeNT alone to TeNT-Fab, even with SEC analysis. The 
binary complexes elute earlier compared to the TeNT alone, with an elution volume that 
corresponds to a stable oligomer of 200 kDa (Figure 2.8). The same result was obtained also 
for the TeNT-Fab110 binary complex (data not shown).            
Fig. 2.7: Size exclusion chromatography of binary 
complexes.  In blue absorbance at 280 nm. (A) SEC 
of TeNT- Fab104.14 binary complex. On the left SDS-
PAGE. It shows that in peak (I) are present both TeNT 
and Fab104.14, and in peak (II) unbounded 
Fab104.14. (B) SEC of TeNT-Fab110 binary complex. 
The same as for Fab104.14. (C) Native-PAGE gel of 
the peaks from the SEC analysis of the both binary 
complexes. First lane Marker (kDa), second lane 
TeNT as control, lane 3 and 4, Fab104.14 and 
Fab110, lane 5 and 6 the binary complexes. We can 
appreciate the molecular shift of the binary 
complexes  respect to TeNT alone. 
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Fig. 2.8: Size exclusion chromatography of binary complexes. In blue absorbance at 280 nm. SEC of TeNT- 
Fab104.14 binary complex compared to TeNT alone,  shown with dotted chromatogram. 
SEC and NATIVE-PAGE analysis of the ternary complex TeNT-FaB104.14-Fab110. We then 
wondered if by putting together TeNT with both Fab molecules, we could obtain a stable 
ternary complex, as for the binary ones. In this way, all the two Fabs together, will be able to 
stabilize the inherent protein flexibility, as well as maintain one constant isoform of TeNT 
during the crystallization process, so favouring it. We used the same reaction conditions, as 
for the binary complexes. Molar ratio 1:1:1 (TeNT:Fab104.14:Fab110), overnight at 4°C, 
shaking. The next day the fraction containing the ternary complex were pulled and 
concentrated until 500 µl, and subsequently loaded on Superdex 200 10/30 gel filtration 
column. As we can seen from the chromatogram there are two peaks (Figure 2.9, A): the 
main peak at 10.2 ml and a second peak at 15 ml elution volume. Two samples corresponding 
to the first peak and to the second were loaded onto SDS-PAGE gel to determine its 
composition. The gel shows that in the peak are present both TeNT, Fab104.14 and Fab110 
which firmly elute as a single molecular specie, instead in the second peak are present the 
unbound Fabs, that elutes at the same elution volume due to the same molecular weight 
(data not shown). Native-PAGE analysis also clearly showed that the main peak corresponds 
to a ternary complex of 250 kDa (Figure 2.9, C). If we compare the main peak of the ternary 
complex with the one of the binary complex, we can observe that it is slightly shifted, and 
elutes earlier. Thus, corresponding to a stable oligomer of 250 kDa (Figure 2.9, B). 
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Fig. 2.9: Size exclusion chromatography of the ternary complex. In blue absorbance at 280 nm. (A) SEC of TeNT- 
Fab104.14-Fab110 ternary complex. (B) SEC of ternary complex (Elution Vol. 10.2 ml) compared with the binary 
complexes (TeNT-Fab104.14 in red. Elution Vol. 11 ml; and TeNT-Fab110 in grey. Elution Vol. 11.5),  and with 
TeNT alone in pink.Elution Vol. 12 ml. (C) Native-PAGE gel of both binary and ternary complexes. 
A 
32 
 
Mouse lethality assay of the ternary complex. At this point, we wanted to see whether the 
analysed binary and ternary complexes, were able to protect mice from tetanus infection. 
Mouse lethality assays with binary and ternary complexes are shown in Figure 2.10, using 
lethality of TeNT as control. The mouse lethality assay of TeNTs with Fabs closely looks like 
the one of TeNT with the respective hu-mAbs. In fact, both binary complexes of TeNT with 
Fabs and the ternary one give a complete protection in vivo. This clearly indicates, that not 
only the interaction TeNT with single Fabs, but also the one with the Fabs together is quite 
stable and strong. 
                            
Fig. 2.10: Mouse lethality assay. The binary complexes tested delay and strongly protect mice against death 
induced by TeNT. Adult CD1 mice injected with 4pg/G TeNT, previously incubated with Fabs. In the figure is 
shown the 1:5 ratio (TeNT:Fabs), which gave the best result. For each condition n=9 mice were used. The 
animals were monitored every day (for 1 week). 
 
 
 
 
 
 
 
 
0 50 100 150 200
0
25
50
75
100 TeNT 4.0 pg/g
Fab 110 1:5
Fab 104.4 1:5
Fab 110+Fab 104.4 1:5
Hours after TeNT Injection
P
e
rc
e
n
t 
s
u
rv
iv
a
l
33 
 
4. CONCLUSIONS 
Tetanus toxin (TeNT) is one of the most poisonous molecules known, the causative agent of 
the neuroparalytic disease tetanus. It acts on the central nervous system by blocking the 
neurotransmitter release and causing spastic paralysis. Although a lot is known about its 
domain organization and mechanism of action, no three dimensional structure is yet 
available. Instead experimental three-dimensional structures has been resolved for the N-
terminal catalytic domain and C-terminal binding domain. Its crystallization has been proven 
to be quite difficult. This probably is due to some intrinsic properties of the toxin, not easy for 
us to be identified and that does not allow the crystallization process to occur. A crystal 
structure analysis will provide a tremendous amount of insights into both the structure and 
function of the protein. Moreover, an understanding of the molecular mechanism at the 
atomic level is a prerequisite for the development of an effective structure-based vaccine to 
treat tetanus victims. This part of my thesis work was aimed in understanding the 
biochemistry of the tetanus neurotoxin through crystallization studies.  
The approach considered in order to have a suitable TeNT protein for crystallization, was that 
of using antibody fragments (Fabs) as tools for stabilizing functionally relevant states of the 
protein. A binder target-protein complex has an enhanced chance to crystallize when a 
particular target protein conformation is stabilized, and the Fabs are quite appropriate. The 
choice of the two Fabs (Fab104,14- that binds the binding domain of TeNT, and Fab104- that 
binds the translocation domain of the toxin) was done in the basis of previous results 
obtained by screening a set of human monoclonal antibodies. Two of these antibodies 
resulted to be very efficient in protecting mice from tetanus infection. So the Fabs that we 
used derived from these two antibodies.  
First we tested the in vitro binding of the two chosen Fabs with the tetanus toxin. An 
overnight reaction was performed at 1:1 molar ratio and the samples analysed through a 
native page gel, in order to detect the complex formation. Gel-filtration experiments show 
co-elution of the TeNT with the respective Fabs, Fab104.14 and Fab110. We were able to to 
reconstitute in vitro a stable and pure TeNT-Fab104.14 and TeNT-Fab110 binary complex. The 
obtained  binary complexes are also active in vivo, by protecting mice from tetanus. Different 
crystallization trials were done with the purified TeNT-Fabs complex.  
The isolation of the ternary complex TeNT-Fab104.14-Fab110 was another result that allowed 
us to demonstrate that the interaction between the two Fabs together and TeNT can be 
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reproduced in vitro. The size exclusion chromatography showed that the ternary complex 
elutes as stable oligomer, indicating that also the two Fabs together are good protein 
partners required for TeNT stabilization. The ternary complex was tested in vivo, and it gives a 
complete protection. Even in this case several crystallization trials were done with the 
purified ternary complex  
A huge amount of crystallization screening were performed, but yet we have not obtained  
good crystals for the study of the experimental three dimensional structure of TeNT. 
Preliminary data from electron microscopy negative staining reveal different conformations 
and heterogeneity of the purified ternary complex, and probably this may be one of the 
reasons why we still have not obtained any crystals. Work in progress in order to have an 
homogeneity of the purified binary and ternary complexes.      
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PART III: FUNCTIONAL ANALYSIS OF BOTULINUM NEUROTOXIN TRAFFICKING 
AT THE NEUROMUSCULAR JUNCTION 
 
 
1. INTRODUCTION 
1.1 Botulinum neurotoxins: molecular structure and mechanism of action 
Botulinum neurotoxins (BoNTs) are bacterial protein produced by Clostridium botulinum 
strains and are the most hazardous toxins known up to now. They block the release of 
neurotransmitters from synaptic vesicles and act in nanogram quantities because of their 
ability to specifically target neurons (Gill, 1982). The botulinum neurotoxins are produced in 
dozens of different isoforms, grouped into eight distinct serotypes (BoNT/A to /H) that exhibit 
amino acid sequence conservation. BoNTs are structurally organized in two main chains: a 
light chain (L, 50 KDa) and a heavy chain (H, 100 KDa) held together by a strictly conserved 
inter-chain disulfide bond and non-covalent interactions (Rossetto et al., 2014; Rummel, 
2015). These two chains based on their functional properties are organised in four domains 
(Figure 3.1): (I) HC-C (25 kDa, in green) is involved in nerve terminal binding and 
internalization (Montecucco, 1986; Binz and Rummel, 2009; Brunger and Rummel, 2009; 
Rummel, 2013;); (ii) HC-N (25 kDa, in purple), as not yet a well-defined role, but it is 
prpopsed that it may contribute to binding by interacting with membrane lipids (Muraro et 
al., 2009; Ayyar et al., 2015; Zhang et al., 2012) (iii) HN (50 kDa, in yellow) assists the 
translocation of the catalytic part of the toxin from the internal part of an intracellular acidic 
compartment into the cytosol (Fischer and Montal, 2007; Montal, 2010; Pirazzini et al., 
2015); (iv) the L catalytic domain (50 kDa, in red) is a metalloprotease that cleaves the SNARE 
proteins interfering with the release of neurotransmitters that result in a reversible 
neuroparalysis (Pantano et al., 2013).   Despite the amino acid sequence variability among all 
BoNT variants, the structure organization is however maintained, as it mechanism of nerve 
intoxication (Pantano et al., 2013). The domain organization of BoNTs is closely related to 
their mechanism of action: (i) functional binding to polysialogangliosides (PSG), highly 
enriched in the neuromuscular junction (NMJ); (ii) membrane translocation across the SV 
membrane driven by a pH lowering, which is physiologically necessary for the 
neurotransmitter refilling of these compartments; (iii) metalloproteolytic activity specific for 
VAMP, SNAP-25, or syntaxin, three proteins that are members of machinery for the 
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neurotransmitter release. In the following sections, will be reviewed more in details relevant 
insight concerning BoNTs mechanism of action. 
                           
Fig. 3.1: Crystallographic structure of isolated BoNT/A1. Crystal structure of botulinum neurotoxin A1 
(BoNT/A1) (PDB 3BTA), showing its organization of individual toxin domains, every of that with a specific role in 
cellular mechanism of intoxication: the HC domain binds specifically to the nerve terminals; the HN domain 
translocate the L chain into the cytosol of the nerve terminal; and L chain is a metalloprotease that cleaves 
specific SNARE proteins, involved in neurotransmitter release, thereby causing neuroparalysis. A peptide belt 
(showing in dark blue), that surrounds the L domain and the inter-chain disulfide bond (orange), links the L 
chain to the HN domain. From Rossetto  et al., 2014. 
 
Membrane binding and the “dual receptor model”. The high potency of BoNTs is mainly due 
to their neurospecific binding which is mediated by the interaction with two receptor 
components. The double receptor model is based on a first binding to a polysialoganglioside 
molecule followed by a second interaction with a protein receptor (Montecucco, 1986). 
Indeed, BoNTs have evolved this ability to bind neurons via two receptors, one with low 
affinity, a polysialogangliosides (PSG), that increases toxin density on the target membrane 
(Binz and Rummel, 2009; Rummel, 2013), and a secondary one the luminal part of an integral 
membrane protein of synaptic vesicles (SV), which triggers the internalization into the 
endocytic pathway (Matteoli et al., 1996) (Figure 3.2).  
More in detail, gangliosides are a large family of glycosphingolipids present on the external 
plasma membrane of  cells and are involved in many pathways like cell signalling, protein 
sorting and are very important for membrane domain formation and organization. 
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Gangliosides are particularly enriched in neurons membrane, especially in axons and 
dendrites where they govern membrane curvature (Ledeen et al., 1993; Sonnino et al., 2007). 
Indeed, this binding of BoNTs to the negatively charged sialic acids of PSG is very efficient 
because these neurotoxins are dipoles, with their positively charged end situated close to the 
binding site. This effect contributes not only to the rapid binding of BoNTs to the nerve 
terminal in vivo, but also to their reorientation that allow the interaction with the second 
receptor. The PSG-binding site of BoNT/A, /B, /E, /F and /G, is located in the HC-C domain, 
outlined by the conserved motif E(or D or Q)...H(or K or G)...SXWY...G (where X is any amino 
acid and “…” denotes a variable. Also, the PSG-binding site for BoNT/C, BoNT/DC and BoNT/D 
is found in a similar position, but the binding motif is different (Karalewitz et al., 2010; 
Strotmeier et al., 2010; Zhang et al., 2010; Karalewitz et al., 2012).  
Subsequently, upon exocytosis the intralumenal domains of the synaptic vesicle proteins are 
exposed and can be accessed by the surface attached neurotoxins. BoNT/B, BoNT/G and 
BoNT/DC bind with their HC-C domain to the lumenal domain of synaptotagmin-I/II (Syt-I, 
Syt-II) ( Nishiki et al., 1994; Nishiki et al., 1996; Dong et al., 2003; Rummel et al., 2004; 
Mahrhold et al., 2006; Chai et al., 2006; Jin et al., 2006; Dong et al., 2007; Peng et al., 2012; 
Bertnsson et al., 2013; Willjes et al., 2013). By contrast, BoNT/A and BoNT/E bind specifically 
to two different segments of the fourth lumenal loop of the synaptic vesicle transmembrane 
protein SV2 (Dong et aL., 2006; Dong et al., 2008; Benoit et al., 2014). SV2C appears to be the 
main receptor involved in BoNT/A binding, while SV2A e SV2B, but not SV2C, mediate BoNT/E 
entry. However all three isoforms are expressed in motoneurons (Benoit et al., 2014). The 
protein receptors of other BoNTs have not been yet fully characterized, although SV2A-C 
seems to play an important role in the uptake mechanism of BoNT/D and BoNT/F (Fu et al., 
2009; Rummel et al., 2009; Peng et al., 2011; Rummel, 2015).   
Thereafter the synaptic vesicle is recycled and the anchored BoNT is endocytosed.  
Acidification of the vesicle lumen triggers membrane insertion of the translocation domain 
followed by pore formation and translocation of the enzymatically light chain to its site of 
action. 
Previously in our laboratory, BoNT/A was visualized for the first time inside small clear 
synaptic vesicles present within the motor nerve terminal of the neuromuscular junction 
(NMJ). It was demonstrated that the translocation of BoNT/A takes place from synaptic 
vesicles and not from the endosomal compartment (Colasante et al., 2013). The mechanism 
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of internalization of other BoNTs remains to be established. By contrast in cultured neuron 
and probably also in vivo, alternative vesicles and trafficking route may contribute to their 
entry (Pellet et al., 2015). Indeed, information concerning the nature of the endocytic vesicle 
involved in the uptake of the other serotypes is still lacking. In this thesis, we will discuss 
about the possible distinctive trafficking exploited by different serotypes of BoNTs. Indeed, 
we show a different immunoflourescence staining between the different serotypes tested 
during binding and internalization.  
 
 
                               
Fig. 3.2: Botulinum neurotoxins mechanism of action within peripheral nerve terminals. The BoNT mechanism 
of action starts with a primary interaction between the HC-C domain and a polysialogangliosides (PSG). 
Subsequent lateral movements make possible the binding of the toxin with a protein receptor which is the 
lumenal domain of a synaptic vesicle protein (step 1). The protein receptor has been identified as 
synaptotagmin I and II for BoNT/B, /DC and /G (crystal structure shown on the lower left-hand side), and SV2 for 
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BoNT/A, /E and /F (crystal structure shown on the right left-hand side); the protein receptor for the remaining 
serotypesis still unknown and it remains to be clarified. This latter binding to the protein receptor is 
fundamental for the internalization of the toxin-receptors complex inside an acidic intracellular compartment 
(step 2) whose nature has been identified as SV for BoNT/A1 (Colasante et al., 2014). Little is known on the 
nature of endocytic compartments exploited by the other BoNT serotypes, however several evidences show 
that the acidification of its lumen triggers a structural rearrangement of L chain and the translocation domain 
(HN) (step 3). This process ends with the reduction of the disulfide bond performed by the thioredoxin 
reductase-thioredoxin system. The free L metalloproteases can now cleave one of the three SNARE proteins 
(step 4) thereby preventing Ca
2+
 elicited release of the neurotransmitter contained insides SV. From Rossetto  et 
al., 2014. 
 
Translocation across the membrane of acidic intracellular compartments. Considering the 
steps of BoNTs cellular mechanism of intoxication in nerve terminals, the membrane 
translocation of the L chain into the cytosol is the least understood in terms of molecular 
mechanism. BoNTs have evolved to use a relevant physiological feature of nerve terminals, 
they exploit the acidification of the synaptic vesicles (SV) lumen carried out by the v-ATPase, 
a proton pump present on their membrane (Sudhof, 2013), that lowers the lumenal pH to 
generate the pH gradient driving the re-uptake of neurotransmitters from the cytoplasm into 
SV (Pantano et al., 2013; Pirazzini et al., 2015). The importance of the v-ATPase in BoNTs 
mechanism of action, is extensively demonstrated by the fact that specific inhibitors block 
BoNTs neurotoxicity (Simpson et al., 1994; Sun et al., 2012). 
Despite the fact that the exact molecular mechanism is still under debate, it is well known 
that the translocation step is mediated by a structural rearrangement of the entire molecule. 
Indeed it is long known that at acidic pH BoNTs forms ion conducting channels, and that this 
channel mediates the translocation of the L chain into the cytosol (Fisher and Montal, 2007; 
Montal, 2010; Koriazova and Montal, 2003; Fischer and Montal, 2013). Montal and 
colleagues gave the major contribution by using the patch clamp technique, and showing 
that the transmembrane ion channel formation in planar lipid bilayers is associated with the 
translocation of the L chain of BoNT/A1 with cleavage of its target protein, SNAP-25. The 
outcomes of these experiments are shown and interpreted with the model reported in Figure 
3.3 (Montal, 2010; Fischer and Montal, 2013). The HN domain of BoNT/A (in yellow), when 
the pH is lowered on the cis side of the patched membrane (corresponding of the SV lumen), 
and when a negative membrane potential is applied, it forms a transmembrane channel that 
chaperons the passage of the L chain (in red) on the trans side (corresponding to cell cytosol).  
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The increasing of the transmembrane current begins with low values (~ 10 pS) corresponding 
to the phase during which the L chain occupies the channel to pass on the other side, and 
raises within 10 minutes to ~ 65 pS or ~ 110 pS, in PC12 cell line (Figure 3.2), thus 
corresponding to the full conductance of a transmembrane channel (Fischer and Montal, 
2007; Fischer et al., 2009; Montal, 2010; Fischer and Montal 2013). Interestingly, this formed 
channel permits the passage of only α-helices but not tertiary structure elements, indicating 
that the L chain has to unfold, at least partially, in order fit within the narrow cavity (15-20 Å 
in diameter) (Figure 3.3, B) (Montecucco, 1986; Kukreja et al., 2006; Cai et al., 2006; Montal, 
2010). 
 
 
Fig. 3.3: Membrane translocation of BoNTs across the membrane of endocytic compartments. (A) The upper 
panel shows the increase of conductance of the plasma membrane at low pH in Neuro2A cell line, induced by 
BoNT/A1. (B) The lower panel shows steps proposed and involved in the membrane translocation of the L chain: 
1) a schematic structure of the toxin; 2) the HN domain at acidic pH inserts into the membrane forming a 
transmembrane channel, hypothetically made of a six α –helices; 3) the translocation of L chain from the acidic 
lumen into the neutral cytosol increases the conductance; 4) complete translocation of the L chain within the 
cytosol where it refolds and the inter-chain disulfide bond is reduced by the Thioredoxin Reductase-Thioredoxin 
system. From Pirazzini et al., 2015. 
 
For a successful translocation mechanism, the disulfide bond must remain intact during the 
initial phase of the process, and must be reduced only when it reaches the trans-side of the 
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membrane. This data are in agreement with the fact that pre-reduced BoNT does not form 
channels and that the reduction at any stage before reaching the cytosolic side aborts 
channel formation and consequently L chain translocation (Fischer and Montal, 2007; Fischer 
and Montal, 2013). Thus the model proposed by Montal and co-workers, suggests the fact 
that upon acidification the BoNT molecules change their structure, HN inserts into the 
membrane and the L chain unfold maintaining only secondary structure elements. Thereafter 
L chain remains connected to the SV till the inter-chain disulfide bond is reduced, and  that is 
the concluding step that conclude the process leaving the HN channel to its full conductance 
(Figure 3.3, A and B).  
However, such a model does not take in account of other important data present in 
literature: i) data from the crystal structure of BoNT/B, and the L chain and HN domain of 
BoNT/A, show that they do not change structure at low pH in solution (Eswaramoorthy et al., 
2004; Galloux et al., 2008), while they undergo conformational changes in the presence of 
PSG or lipids (Montecucco, 1986; Fu et al., 2002; Puhar et al., 2004; Sun et al., 2011); ii) from 
membrane photolabelling studies that is bypassed the internalization step and induced the 
translocation of the L chain directly from the cell surface, it has been found that BoNTs are 
attached to the membrane by two receptors and that the membrane translocation occurs 
within few minutes at 37 °C in the pH range 4.5-6, this is consistent with the pH within the 
synaptic vesicle, and with the fact that very little translocation is taking place at 20 °C 
(Pirazzini et al., 2011); iii) the replacement of three carboxylate residues with the 
corresponding amides in BoNT/B, doesn’t allow their protonation, thus the L chain to enter 
the cytoplasm quicker, increasing toxicity (Pirazzini et al., 2013). 
All these data, taken together suggest that there is not only one single pH sensor in BoNTs, 
but several carboxylates that have high pKa values and play an important role in the low pH-
driven release of the L chain into the cytosol.  
An updated model for BoNT translocation has been proposed, shown in Figure 3.4. (Pirazzini 
et al., 2014). BoNTs bind to its two receptors within the SV lumen, which initially has a 
neutral pH, immediately after endocytosis. Then, the v-ATPase pumps protons and SV lumen 
becomes progressively more acidic. There is no a single pH sensor in BoNTs, but the 
conserved carboxylates predicted to have higher pKa, get protonated, and drive the partially 
protonated BoNT toward the membrane surface involving the disulphide-containing face of 
the toxin. Here, the pH is more acidic with respect to the lumen allowing further protonation 
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of other carboxylates. The subsequent molecular events are currently unknown, but on the 
basis of earlier studies, it can be speculated that the L chain becomes a “molten globule”, a 
protein state variant that retains native secondary structure and then it increases 
hydrophobicity, thus enabling its insertion and passage across the membrane (Pirazzini et al., 
2013; Rossetto et al., 2014; Pirazzini et al., 2015).  
It has been proposed that the long α-helices of HN may break by generating amphipathic 
helices with the length of 20-24 residues that, together with the other amphipathic helices of 
the HN domain insert in the membrane, by forming a laterally opened transmembrane 
channel. The arc-shaped membrane inserted HN may have a function as chaperone for the 
translocation of the L chain, as suggested by Koriazova and Montal (Koriazova and Montal, 
2003; Montal 2010; Fischer and Montal, 2013). By facing the neutral pH of the cytosol, the L 
chain of BoNTs deprotonates and refolds into the metalloprotease domain whilst the 
membrane inserted HN closes laterally to form a stable ion channel. The process is then 
closed by the reduction of the disulfide bridge, that releases the L chain and its protease 
activity, attaining the HN channel for its full conductance. 
 
Fig. 3.4: A novel model proposed for the translocation step in botulinum mechanism of action . 1) Schematic 
representation of the four domains of the toxin in different colours: L (red), HN (yellow), HC-H (purple) and HC-C 
(green). The HC-C domain, binds to its two receptors: the polysialoganglioside (blue triangle) and the lumenal 
part of SV protein (SV2 or synaptotagmin, orange rectangle). 2) The v-ATPase protons pump and the vesicle 
lumen is acidified and the carboxylate residues are protonated. 4) A net positive charge is acquired by the 
protein at this face that can eventually fall down on the anionic membrane surface; low pH and lipid interaction 
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cause a combined and sequential structural. 5) L crosses to the cytosolic side, refolds and then is released upon 
reduction of the disulfide bridge. From Pirazzini et al., 2015. 
Whether the situation of the membrane translocation of BoNTs is actually as it was 
previously described is currently unknown. This last mechanism is a speculation and 
additional studies are needed to clarify this essential step and still unclear of the BoNT 
intoxication process. 
 
The disulphide bond reduction. The interchain disulphide bond plays a functional role in 
cellular BoNTs intoxication. The first evidence was given by the lack of toxicity in vivo of 
previously reduced neurotoxin (Schiavo et al., 1997). Fischer and Montal have demonstrated 
that for a successful translocation, the L chain has to remain linked to H via the inter-chain SS 
bridge and that its reduction is the concluding event, that which frees the L chain enabling 
the metalloprotease activity (Fischer and Montal, 2007). Indeed, the premature reduction of 
this bond, at any stage before its exposure to the cytoplasm, abolish the L chain 
translocation, thus indicating that it plays a fundamental role within the cellular intoxication 
process and that it has to reach intact the cytosolic side of the membrane (Pirazzini et al., 
2011; Rossetto et al., 2014). All these data taken together indicate that the reduction of the 
interchain disulfide bond within nerve terminal cytosol may be a “conditio sine qua non” to 
the metalloprotease activity of BoNTs, thus representing a target for the development of 
mechanism-based antitoxins (Pirazzini et al., 2015). The SV lumen of most intracellular 
organelle is oxidant, while the cell cytosol has a reducing potential, which is kept by a large 
number of redox couples (Arner and Holmgren, 2000; Holmgren et al., 2010; Hanschmann et 
al., 2013). The reduction of protein disulfides bonds is catalysed in the cell by several 
enzymatic systems. Two of which are the glutathione-glutaredoxin system and the NADPH-
Thioredoxin reductase (TrxR)-Thioredoxin (Trx). It was demonstrated that the TrxR may be 
involved in the reduction of the interchain disulfide bond of BoNTs. It was found that 
Auranofin, the most potent TrxR inhibitor identified so far, prevented the toxicity of BoNT/B, 
/C and /D (Pirazzini et al., 2013; Pirazzini et al.,2014). Instead, buthione sulfoximine, a 
compound that substantially reduce glutathione intracellular levels, had no inhibitory activity, 
indicating that the glutathione-glutaredoxin system is not involved in the entry of BoNTs in 
the cytoplasm (Pirazzini et al.,2013). 
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The L chains of BoNTs are metalloproteases specific for the SNARE proteins. Once that the L 
chain is free in the cytosol, it functions as a Zn2+ dependent endopeptidase that exclusively 
hydrolyses distinct peptide bonds of neuronal SNARE proteins: VAMP (vesicle-associated 
membrane protein; also called synaptobrevin), SNAP-25 (synaptosomal-associated protein of 
25 kDa) or syntaxin which are cleaved at single sites. More in details, BoNT/A, and BoNT/E 
cleave SNAP25 (Schiavo et al., 1993; Blasi et al., 1993), BoNT/B, BoNT/D, BoNT/F and BoNT/G 
cleave VAMP (Schiavo et al., 1992; Schiavo et al., 1993), instead, BoNT/C is unique because 
cleave both SNAP25 and syntaxin (Pantano et al., 2013). The inactivation of any of these 
three proteins inhibits the neurotransmitter release, this is the strongest evidence that the 
three SNARE proteins form the core of the neuroexocytosis nanomachine (Sutton et al., 
1998; Schiavo et al., 2000; Binz, 2013; Pantano et al., 2013). The SNARE family of proteins 
includes several isoforms and they are differentially expressed in many non-neuronal cells 
and tissues. BoNTs cleave SNARE proteins by removing large cytosolic segments, which 
prevents the formation of the SNARE complex. Instead, only BoNT/A and BoNT/C remove 
only a few residues from the C-terminal of SNAP-25 and, this SNAP-25 truncated form are still 
able to form a stable SNARE complex; thus, the molecular mechanism of BoNT/A and 
BoNT/C-induced neuroparalysis still remains to be clarified. The cleavage of a SNARE protein 
prevents the assembly of the SNARE complex, which is fundamental for the fusion of the 
vesicles containg the neurotransmitter, with the presynaptic membrane. As long as the L 
chain remains active, the nerve terminal remains paralysed.  
Therefore, BoNTs can be used as tools to determine the effect of knocking-out specific 
proteins of the  SNARE complex in cell physiology (Pantano et al., 2013). 
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2. AIM OF THE WORK 
Botulinum neurotoxins (BoNTs) are bacterial protein produced by Clostridium botulinum 
strains and are the most hazardous toxins known up to now. They block the release of 
neurotransmitters from synaptic vesicles and act in nanogram quantities because of their 
ability to specifically target neurons. Eight different serotypes are known, named A to H, and 
exhibit amino acid sequence conservation. BoNTs are peculiar with respect to their pre-
synaptic membrane binding which is mediated by a polysialoganglioside and by a protein 
receptor consisting of the luminal portion of a synaptic vesicle membrane protein. BoNT/A, 
BoNT/E and BoNT/F bind to SV2, while BoNT/B, BoNT/G bind to synaptotagmin. To date the 
protein receptor of other BoNT serotypes, BoNT/C and D has not been conclusively 
determined. While the intoxication step has been clarified, endocytosis and membrane 
translocation remain largely unknown. The fact that the known BoNT receptors are in the 
luminal domain of synaptic vesicles strongly suggests that BoNTs are endocytosed inside 
synaptic vesicles at peripheral nerve terminals. However, their actual presence inside vesicles 
and the type of synaptic vesicles has not been determined. Using immunoelectron 
microscopy technique BoNT/A1 was visualized for the first time inside small clear synaptic 
vesicles present within the motor nerve terminal of the neuromuscular junction (NMJ).  
Taken in consideration this, the aim of my work was to study the initial trafficking events for 
other BoNTs, in particular for BoNT/A5/B and BoNT/D. We focused on BoNT/A5 and /B 
because most frequently associated with human botulism, instead BoNT/D frequently 
associated with animal botulism. Also the choice of these BoNTs was due to the different 
time required for intoxication, BoNT/A5 and /D translocate their L-chain very rapidly, instead 
BoNT/B intoxication is longer. I have prepared the binding domains (HCs) of these BoNTs, 
which are both necessary and sufficient for binding to the neuronal surface and 
internalization. HC-BoNTs are considered ideal tools to exploit the initial trafficking of BoNTs 
intoxication. Each binding domain was prepared fused with and appropriate fluorescent tags 
in E.coli, in order to directly visualize their distribution at the NMJ using fluorescence 
microscopy. 
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3. MATERIAL AND METHODS 
Animals. For in vivo experiments, adult male CD1/Swiss-Webster mice weighing 26-28g were 
used. Instead, for neuronal culture rats from 6- to 8-days-old were sacrified. All experiments 
were performed in accordance with the European Communities Council Directive 
n°2010/63/UE and approved by the Italian Ministry of Health. 
Antibodies and reagents. Antibodies were obtained from the following sources: mouse anti-
His tag (Novagen, #70796), rabbit anti GFP (Abcam, #6556), Alexa Flour-555 conjugated α-
bungarotoxin (Invitrogen, #B3545). Flourescently conjugated secondary antibodies were 
obtained from Merck Millipore. The remaining reagents were sourced from Sigma unless 
stated otherwise.  
Construction of the HC-BoNTs expression vectors. The DNA encoding the following HC-
BoNTs: cp-YFP-HC-BoNT/A5 (residues 876-1296); mCherry-HC-BoNT/D (residues 863-1276); 
GFP-HC-BoNT/B (residues 832-1290) was synthesized (GeneArt Gene Synthesis, Thermo 
Fischer Scientific) with optimal codon bias for Escherichia coli expression. The DNA fragment 
was amplified and subcloned into unique BamHI and HindIII restriction sites of pET28a+ 
vector expression vector (Novagen) for HC-BoNT/A5 and /D. Instead, HC-BoNT/B was 
subcloned into unique XhoI and HindIII restriction sites of pRSETa expression vector (Thermo 
Fischer Scientific). Correct insertion of HC-BoNTs DNA was confermed by DNA sequencing at 
BMR Genomics (Padova). HC-BoNT/A5-pET28a+ and HC-BoNT/D-pET28a+ were tranfromed 
into BL21(DE3) (Novagen) for protein expression. HC-BoNT/B-pRESTa was transformed into 
BL21(DE3)pLysS (Thermo Fischer Scientific) for protein expression.  
Purification of recombinant HC-BoNTs. E.coli BL21(DE3) HC-BoNT/A5-pET28a+ and HC-
BoNT/D-pET28a+, were grown overnight on LB plates with 50µg/ml kanamycin and 
preinoculated into LB medium (20 ml) containing the same antibiotic 37°C overnight. The 
preculture was then inoculated into LB medium (1:50) containing kanamycin. The cells were 
grown at 37°C for 2 h at 200 rpm to an optical density of 0.6-0.8. Protein expression was 
induced with 1mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) and followed by on 
overnight culture at 16°C under continuous shaking. The cells were harvested by 
centrifugation at 5000 rpm for 15 min, and the cell pellet was resuspended in the following 
lysis buffer: 20mM Tris-HCl (pH 7.6), 500mM NaCl, 10mM Imidazole, EDTA-free protease 
inhibitor (Roche), 1 mg/ml lysozyme, DNase, 1mM PMSF, 5% glycerol. After 1h incubation 
51 
 
with the lysis buffer at 4°C the cells were sonicated. The crude lysate was clarified by 
centrifugation at 22000 rpm for 45 min at 4°C and filtration through a 0.45 µm membrane 
filter. The supernatant was loaded onto a prepacked HisTrap Ni column (GE Healthcare) 
equilibrated with 20mM Tri-HCl (pH 7.6), 500mM NaCl, 10mM imidazole. After loading the 
column was washed with 20mM Tri-HCl (pH 7.6), 500mM NaCl, 20mM imidazole, for about 
10 column volume.  The protein was eluted over a 0-500 mM imidazole gradient in the same 
buffer. The fractions containing the protein were pooled, concentrated and further purified 
by size-exclusion chromatography using a Superdex 200, 10/300GL column (GE Healthcare), 
pre-equilibrated with 20 mM Tris-HCl pH 7.4; 150 mM NaCl. The pure protein fractions were 
pooled and concentrated using 30 kDa cutoff membrane filter (Amicon Millipore). The final 
concentration of the proteins was determined by absorption spectroscopy at 280 nm. The 
samples of each purification step are analysed for their purity on 4-12% NuPage (Life 
Technologies). Protein identity was confirmed by Western Blotting using an anti-His tag 
antibody (Novagen, 1:1000) . 
The same expression and purification protocol was used also for the HC-BoNT/B. 
Immunoblotting. For immunoblotting analysis equal amounts of protein were loaded onto a 
4-12% NuPage gel and separated by electrophoresis in MES buffer (Life technologies). 
Proteins were then transferred onto Protran nitrocellulose membranes (Whatman) and 
saturated for 1 h in PBST (PBS 0.1% Tween20) supplemented with 5% non-fatty milk.in 
Incubation with primary antibodies was performed overnight at 4°C. The membranes were 
then washed three times with PBST and incubated with secondary HRP-conjugated 
antibodies. Finally, membranes were washed three times with PBST and twice with PBS. 
Visualization was carried out using Luminata Crescendo (Merck Millipore).  
Neuronal culture. Primary cultures of rat cerebellar granule neurons (CGNs) were prepared 
from 6- to 8-days-old rats. Cerebella were isolated, mechanically disrupted and then 
trypsinized in the presence of DNase I. Cells were then plated into 24 well plates, pre-coated 
with poly-L-lysine (50 μg/mL), at a cell density of 4 x 105 cells per well. Cultures were main-
tained at 37 °C, 5% CO2, 95% humidity in BME supplemented with 10% fetal bovine serum, 
25 mM KCl, 2 mM glutamine and 50 μg/mL gentamicin (indicated as complete culture medi-
um). To arrest growth of non-neuronal cells, cytosine arabinoside (10 μM) was added to the 
medium 18–24 h after plating. 
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HC-BoNTs binding and internalization into neurons. CGNs ate 6-8 DIV were washed in phos-
phate-buffered saline (PBS) and incubated with 200 nM of each HcBoNT in 500 μl buffer (15 
mM HEPES, 145 mM NaCl, 2.2 mM CaCl2, 0.5 mM MgCl2, pH 7.4) supplemented with either 
low potassium (5.6 mM KCl) or high potassium (56 mM KCl) for 1 h at  37°C and 5% CO2. After 
the treatment, CGNs were then washed (3X) with PBS, fixed for 10 minutes at RT with 4% 
paraformaldehyde in PBS, and then quenched (50 mM NH4Cl in PBS) for 20 minutes. They 
were directly imaged or permeabilized and stained with a primary antibody specific for the 
fluorescent tag of each HC. For immunofluorescence, cells were permeabilized with 0.1% 
(v/v) TritonX-100 in PBS for 15 minutes at RT, and washed (3X) in PBS. Then were blocked in 
10% (vol/vol) fetal bovine serum, 2.5% (wt/vol) cold fish skin gelatin, 0.1% Triton X-100, 
0.05% Tween 20 in PBS, and the primary antibody rabbit α-GFP (Cell Signaling, 1:1000), was 
incubated overnight at 4°C in 5% (vol/vol) fetal bovine serum, 1% (wt/vol) cold fish skin gela-
tin, 0.1% Triton X-100, and 0.05% Tween 20 in DPBS. Cells were washed 3 times and incubat-
ed for 1 h with the secondary antibody goat α-rabbit Alexa Flour- 488 (Life Technologies, 
1:200). Washed again (3X) with PBS. Then coverslips were mounted using Fluorescent 
Mounting Medium (Dako, S3023) and examined by confocal Leica SP5. Images were collected 
with the same lamp intensity and exposure time.  
In vivo injection of HC-BoNTs and NMJ Immunohistochemistry. For in vivo experiments, 
adult mice CD1/Swiss-Webster weighing 26-28g, were anesthetized with isoflurane, followed 
by injection of HcBoNTs (1 μg) in proximity of the LAL muscle. After 10 minutes the mice 
were sacrified, LAL muscle dissected and fixed in 4% (wt/vol) PFA in PBS for 30 min at RT. 
Samples were quenched and washed (3X) with PBS, before staining for 30 minutes at RT with 
Alexa Flour-555 conjugated α-bungarotoxin (Invitrogen B3545, 1:200). Neuromuscular junc-
tions were analysed with a Leica SP5 confocal microscope equipped with a 63× HCX PL APO 
NA 1.4. Laser excitation line, power intensity, and emission range were chosen according to 
each fluorophore of BoNTs. 
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   4. RESULTS AND DISCUSSION 
Expression and purification of the BoNT-HCs. Synthetic genes encoding E. coli codon-
optimized cpYFP-HC-BoNT/A5 (residues 876-1296); mCherry-HC-BoNT/D (residues 863-
1276); GFP-HC-BoNT/B (residues 832-1290) were synthesized at the indicated source. The 
synthesized DNA was further successfully subcloned into an appropriate expression vector.   
Protein expression of each HC in E. coli BL21(DE3) for BoNT/A5 and /D, and BL21(DE3)pLysS 
for BoNT/B was optimized by titration of induction temperature and IPTG concentration. 
Purification protocols were developed for each HC-BoNT serotype by adjusting the purifica-
tion temperature and ionic strength of the buffers in the chromatography steps. The three 
different fluorescent tags (cpYFP, mCherry and GFP) were chosen in order to visualize the 
HC also in experiments of co-incubation and co-injection. E.coli produced HC-BoNT/A5/D 
and /B as soluble    80   a,       a,   83 kDa proteins respectively (Molecular weights are 
calculated considering also the fluorescent tag of each HC-BoNT). While the overall expres-
sion levels of the three serotypes of HCRs in E. coli were similar, differences in final yields 
were due primarily to the differential solubility of the HC-BoNTs when extracted from the 
cell lysates (>90% for HC-A5 and HC-D to ∼15% for HC-B). The two-step purification, utiliz-
ing affinity chromatography and gel filtration, was sufficient to yield purifications of each 
HCR to >80% purity, as detected by SDS-page analysis. Western blot analysis against the N-
terminal 6xHis tag of each HC-BoNT confirmed the protein identity (Figure 4.1, B and C). The 
final yield of soluble HCs ranged from ∼2 to 10 mg in batch culture. 
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Fig. 4.1: Purification of HC-BoNT/A5/D and /B. (A) Ribbon diagram of the HC-BoNTs prepared for this work. 
They were expressed as 6-His-tag fusion proteins in E. coli. Proteins were purified by affinity- and size-exclusion 
chromatography. (B) Five micrograms of each HCR was subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis. The gel was stained with Coomassie blue and is shown. To the left are the migrations of three 
molecular size markers (kDa). (C) Western blot analysis using anti His tag antibody in order to identify the 
proteins purified.  
Binding and internalization of the HC-BoNTs into neuronal cells. The first step of the cellular 
intoxication mechanism is the specific binding of BoNTs to peripheral nerve endings, followed 
by their internalization via endocytosis into not well identified vesicular compartments for 
the BoNT serotypes. To better investigate this step, we took advantage of the binding 
domains, that fully maintain the capability of parental BoNTs, to bind to the presynaptic 
membrane of neurons and to be endocytosed. The use of cultures cerebellum granular 
neurons (CGNs) offers a simple and a rapid way to test the specificity and functionality of the 
prepared recombinant binding domains of BoNT serotypes. The 1 h incubation with 200 nM 
of each HC-BoNT at 37°C, gave a high specific staining at the axon of the neuronal cells, 
compared to the controls in which CGNs were in incubated with 200 nM recombinant GFP 
and mCherry (Figure 4.2, A). Interestingly, the three HCs used, display clearly different 
patterns of staining, suggesting that they may be internalized inside different compartments 
(Figure 4.2, B).   
 
55 
 
 
Fig. 4.2: Immuncytochemical alanalysis of HC-BoNT/A5/D and /B in CGNs. (A) untreated CGNs as control, and 
CGNs treated with 200 nM of each fluorophore: GFP and mCherry. (B) CGNs were treated with 200 nM of each 
HC-BoNT at 37 °C for 1 h. Samples were fixed and directly stained for all the three HCs. The images shown are 
representative of three independent experiments. Scale bar, 15 µm. 
Binding and internalization of the HC-BoNTs into the neuromuscular junction. After we 
validated in vitro the specificity of  the prepared HCs, we carried out in vivo experiments at 
the neuromuscular junction, the site of action of BoNTs. 1 µg of each HC-BoNT was injected 
near the level of the LAL muscle, and then analysed for the staining of NMJs. The images of 
this analysis, are shown in Figure 4.3. They clearly indicate, that the HCs label only motor 
nerve terminals within the boundaries defined by the pos-synaptic nicotinic acetylcholine 
receptor, visualized here by the very specific binding of fluorescent α- BTX. Thus, the 
recombinant HCs fully maintain the capability of parental BoNTs. The NMJ staining clearly 
shows that the HC binding is restricted to the presynaptic membrane. However, the level of 
resolution of this analysis does not allow us to distinguish toxin bound to the nerve terminal 
surface from the one internalized.   
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Fig. 4.3: The NMJ stained with HC-BoNT/A5/D and /B. The botulinum neurotoxin binding domains bind to the 
axon terminal of the mouse NMJ, as shown by confocal fluorescent microscopy. A top view of four different 
NMJs revealed by the staining of the post-synaptic acetylcholine receptors with Alexa 555-labeled α-
bungarotoxin (α-BTX). (A) NMJ as control, and from mice injected with 1 µg each fluorophore: GFP and mCherry, 
as control for aspecific binding (B) NMJ stained HC-BoNT/A5. Showing cpYFP fluorescence distributed along the 
motor nerve terminal and restricted to the NMJ defined by the α-BTX s staining. (C) and (D) The same for the 
NMJ stained with mCherry-HC-D and GFP-HCB. Side view of the NMJs clearly shows that the labeling from each 
HC-BoNT is mainly found at the presynaptic side of the nerve terminal e does not co-localize with α-BTX 
(Merge). The  images shown are from three independent experiments. Scale bar, 20 µm.    
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In vivo co-injection of two different HC-BoNTs: the HC-A5 and HC-D at the level of the LAL 
muscle. Considering that the HC-BoNTs are conjugated with different fluorophores, we can 
evaluate their different staining by co-injection and directly visualize their staining through 
fluorescent microscopy. Again 1 µg of cpYFP-HC-BoNT/A5 and 1 µg of mCherry-HC-BoNT/D, 
were co-injected at the level of LAL muscle. After 10 minutes the muscle was dissected and 
the NMJs analysed at confocal microscope. The images are shown in Figure 4.4. They clearly 
indicate a complete co-localization of the two different HC-BoNTs, as we can appreciate from 
the immunoflourescent staining. It seems as the two BoNTs have the same initial trafficking 
pathway at the NMJ and bind the same protein receptor. However, further analysis are 
required to better confirm this data.  
 
Fig. 4.4: The NMJ stained with HC-BoNT/A5 and /D. A top view of the NMJ stained with 1 µg of cp-YFP-HC-
BoNT/A5 and 1 µg mCherry-HC-BoNT/D. Side view of the NMJs clearly shows that the labeling from each HC-
BoNT is mainly found at the presynaptic side of the nerve terminal and completely co-localize with each other. 
The  images shown are from three independent experiments. Scale bar, 20 µm.    
In vivo co-injection of two different HC-BoNTs: the HC-B and HC-D at the level of the LAL 
muscle. We then performed another co-injection experiment with the two other HC-BoNTs: 
GFP-HC-BoNT/B and mCherry-HC-BoNT/D. The experiments was perfomed as previously 
explained for the co-injection of the other couple of HCs. Again, images are shown in Figure 
4.5. In this case they indicate a partial co-localization of the two HC-BoNTs tested. The 
staining seems to be different for the two BoNTs. As reported, BoNT/B and BoNT/D have 
different time required for intoxication and due to this they may follow a different pathway 
for their trafficking. Anyway, the experiment was performed just at one timepoint, 10 
minutes. It would be interesting to further investigate this difference also at other 
timepoints. 
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Fig. 4.5: The NMJ stained with HC-BoNT/B and /D. A top view of the NMJ stained with 1 µg of GFP-HC-BoNT/B 
and 1 µg mCherry-HC-BoNT/D. Side view of the NMJs clearly shows that the labeling from each HC-BoNT is 
mainly found at the presynaptic side of the nerve terminal and partially co-localize with each other. The  images 
shown are from three independent experiments. Scale bar, 20 µm.    
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5. CONCLUSIONS 
The high potency of BoNTs is mainly due to their neurospecific binding at the level of the 
peripheral nerve terminal which mediated by the interaction with two receptor components. 
All BoNTs bind first to gangliosides abundantly present on neuronal membranes. Then, upon 
endocytosis they reach their protein receptor, different for each BoNT serotype. The cell 
binding is mediated by the 50 kDa HC-domain. The N-terminal HC mediates the binding with 
the gangliosides, instead the C-terminal HC mediates the one with the protein receptor.  
BoNT/B, BoNT/G and BoNT/DC bind with their HC- domain to the lumenal domain of 
synaptotagmin-I/II (Syt-I, Syt-II). By contrast, BoNT/A and BoNT/E bind specifically to two 
different segments of the fourth lumenal loop of the synaptic vesicle transmembrane protein 
SV2. The protein receptors of other BoNTs have not been yet fully characterized, although 
SV2 seems to play an important role in the uptake mechanism of BoNT/D and BoNT/F. The  
known BoNT receptors are in the luminal domain of synaptic vesicles strongly suggests that 
BoNTs are endocytosed inside synaptic vesicles at peripheral nerve terminals. However, their 
actual presence inside vesicles and the type of synaptic vesicles have not been determined.  
This part of my thesis work, aimed in studying the initial trafficking pathway of BoNT 
serotypes at the level of the neuromuscular junction (NMJ). The most important informations 
delivered by my work are: i)  the recombinant binding domain of BoNTs (HC-BoNTs) are ideal 
tools to exploit the initial trafficking pathways. They are both necessary and sufficient for 
binding to the neuronal surface and internalization. I demonstrated in vitro and in vivo, that 
this property is completely conserved since they label in a very specific way only motor nerve 
terminals; ii)  the NMJ fluorescent staining with HC-BoNT/A5 and mCherry-HC-D clearly show 
a complete co-localization of the two proteins, supporting the hypothesis of the same protein 
receptor for BoNT/A5 and BoNT/D. Therefore, in agreement with several published data 
(Peng et al., 2011; Rummel, 2015); iii) Instead, the fluorescent staining of NMJ with GFP-HC-
BoNT/B and mCherry-HC-D show a partial co-localization of the two proteins. Supporting the 
fact that the time required for the intoxication is different for BoNT/B and BoNT/D, thus they 
may follow a different vesicular trafficking. However, further analysis are required to better 
clarify the distribution of BoNTs at the NMJ, in particular high resolution techniques such as 
electron microscopy.  
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